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Wound healingChronic injury often triggersmaladaptivewound healing responses leading to the development of tissue ﬁbrosis
and subsequent organ malfunction. Inﬂammation is a key component of the wound healing process and
promotes the development of organ ﬁbrosis. Here, we review the contribution of Toll-like receptors (TLRs) to
wound healingwith a particular focus on their role in liver, lung, kidney, skin andmyocardialﬁbrosis.Wediscuss
the role of TLRs on distinct cell populations that participate in the repair process following tissue injury, and the
contribution of exogenous and endogenous TLR ligands to the wound healing response. Systemic review of the
literature shows that TLRs promote tissue repair and ﬁbrosis in many settings, albeit with profound differences
between organs. In particular, TLRs exert a pronounced effect on ﬁbrosis in organs with higher exposure to
bacterial TLR ligands, such as the liver. Targeting TLR signaling at the ligand or receptor level may represent a
novel strategy for the prevention of maladaptive wound healing and ﬁbrosis in chronically injured organs. This
article is part of a Special Issue entitled: Fibrosis: Translation of basic research to human disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The capacity to detect tissue injury and to initiate adequate repair
mechanisms is indispensable for the survival of all higher species. A
common aspect of all types of injury – caused by infectious, physical,
chemical or immune processes – is a compositional change of the
cellular environment leading to the presence of novel molecular
patterns. These patterns are recognized by a group of receptors
termed pattern recognition receptors (PRRs), and trigger speciﬁc
responses that promote the restoration of tissue function, including
inﬂammation and wound healing.
Pathogen recognition is critical for survival in an essentially hos-
tile environment that is full of potentially infective microorganisms.
Detection systems for molecular patterns characteristic for pathogens
(pathogen-associated molecular patterns=PAMPs) developed early
in evolution, and are present in most species including plants and in-
vertebrates [1,2]. Toll-like receptors (TLRs) are a group of highly
conserved pattern recognition receptors that signal the presence of
various PAMPs to cellular constituents of the innate and adaptive im-
mune system. Upon binding to distinct biochemical components of
protozoa, bacteria and viruses, TLRs trigger immune responses via
NF-κB-dependent and interferon regulatory factor (IRF)-dependent
mechanisms. In addition to their function as pathogen recognition
receptors, TLRs may also be activated by endogenous ligands termeds: Translation of basic research
olumbia University, College of
, 1150 St. Nicholas Ave., New
12 851 5461.
e).
rights reserved.damage-associated molecular patterns (DAMPs), which are either
inaccessible to the immune system under physiologic conditions or
undergo changes in response to injury, leading to recognition by PRRs.
After tissue injury, these patterns are unmasked or released from
damaged cells, and subsequently trigger inﬂammation via TLRs and
other PRRs. Accordingly, TLRs can be considered as master safeguards
of the structural integrity of tissue: activated through molecular
indicators of infection or injury, they exert a key role in initiating
countermeasures that repair the wound and protect the host from
further damage.
Inﬂammation and wound healing are tightly linked processes as
demonstrated by the need for inﬂammatory signals to recruit both ﬁ-
broblasts and macrophages for tissue repair and removal of debris.
However, sustained inﬂammation may lead to maladaptive processes
like loss of functional parenchyma, ﬁbrosis and carcinogenesis in a vari-
ety of organs [3–5] (see Fig. 1). TLR signaling in particular has been
identiﬁed as a trigger of inﬂammation leading to dysfunctional wound
healing in several chronic diseases [5]. Here, we will review the role of
TLRs in the regulation of wound repair and ﬁbrogenesis in the setting
of chronic injury, with a particular focus on ﬁve main organs, which
are commonly affected by chronic inﬂammation and maladaptive
wound healing responses: the liver, kidney, lung, skin and heart. Insight
into the complex interactions between TLRs and their ligands may re-
veal novel targets for the prevention or treatment of these maladaptive
responses to chronic injury.
2. Wound healing and the danger hypothesis
Despite being sterile, tissue injury often leads to profound inﬂam-
mation [6]. Inﬂammatory, ﬁbrogenic and regenerative responses are
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to contain damage and to restore and maintain tissue function
through recruitment of several types of specialized cells: platelets
and ﬁbroblasts provide mechanical stability to the wound in short
and long terms, phagocytic leukocytes combat potential pathogens
and clear the site of injury from dead cells and debris, and progenitor
or stem cells replace functional epithelium. Inﬂammation may be ini-
tiated via acellular biochemical reaction cascades such as the comple-
ment system and coagulation cascade, and via the activation of
resident immune cells. Both lead to the recruitment of circulating
white blood cells into the injured tissue and the production of dif-
ferent cytokines, which further amplify inﬂammation and cell re-
cruitment, or regulate important aspects of tissue repair such as
regeneration and ﬁbrogenesis. The inﬂammatory phase of wound
healing resolves within several days and transitions into a regenera-
tive phase, characterized by extracellular matrix (ECM) production
through activated and proliferating ﬁbroblasts, as well as angiogen-
esis, re-epithelialization andwound contraction. Ultimately, the pro-
visional matrix remodels into the “pre-injury state”, or matures into
scar tissue.
Numerous mediators that are essential for inﬂammation, wound
healing and ﬁbrogenic responses are well-established including in-
ﬂammatory cytokines, TGFβ, PDGF and several chemokines [7].
However, it is not well understood through which mechanisms
cells sense the presence of tissue injury and initiate these responses
in the ﬁrst place. One hypothesis is that the activation of the coagu-
lation cascade following damage of vascular endothelial cells is a
major stimulus for wound healing and inﬂammation, as demon-
strated by proinﬂammatory and proﬁbrogenic effects of cleaved
clotting factors on tissue-resident and circulating cells [8–11], as
well as the release of ﬁbrogenic mediators such as serotonin, PDGF
and TGFβ from activated platelets or endothelial cells [7,12–14]. A
second hypothesis is that the encounter with unknown molecular
patterns released from damaged or injured cells (DAMPs) triggers
inﬂammatory, ﬁbrogenic and regenerative responses in speciﬁc
cell types [15–17]. Finally, physical changes in the extracellular en-
vironment such as an increase in pressure and tissue stiffness may
also trigger or amplify ﬁbrosis via activation of ﬁbrogenic cell
populations through mechanoreceptors [18–20]. These hypothesesTissue repair
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Fig. 1. Central role for pattern recognition receptors (PRRs) in wound healing
responses. After tissue damage, molecular indicators of injury or stress activate
pattern recognition receptors to induce measures that contribute to the restoration
of tissue integrity. Chronic injury may trigger maladaptive wound healing through
the same effector systems, and ultimately lead to ﬁbrosis and cancer.are not mutually exclusive, and it is likely that the coagulation cas-
cade, DAMPs and physical forces co-operatively regulate wound
healing responses.
DAMPs are a growing group of signature molecules comprising
biochemical entities as diverse as nucleic acids, extracellular matrix
fragments, cytoskeleton components, small molecules like uric acid
and ATP, as well as large proteins such as heat shock proteins (HSPs),
S100 proteins or high mobility group box protein 1 (HMGB1) [21–26].
Under physiologic conditions, thesemolecules do not trigger inﬂamma-
tion due to seclusion in intracellular compartments or physicochemical
properties that render them inert to PRRs. After tissue injury, however,
DAMPs are either released into the extracellular space or undergo
chemical changes, leading to recognition by PRRs expressed by immune
cells and other cell types. Based on these insights, it has been suggested
that the immune system has evolved not only to detect patterns that
signal foreignness, but also to globally detect patterns that signal danger
[27]. In the setting of chronic injury, DAMPs and their receptors may
contribute to maladaptive wound healing by triggering chronic inﬂam-
mation and activation of ﬁbrogenic cell populations [5,28,29].
3. Toll-like receptors and signaling
Toll, the foundingmember of the TLR family,was describedmore than
20 years ago as a regulator of dorsoventral polarization processes in the
embryogenesis of Drosophila melanogaster [30]. Subsequently, a vital
role of Toll in the induction of an immunological defense against fungal
and bacterial infections was uncovered, and homologous receptors in
vertebrates were identiﬁed [31–33]. In contrast to Drosophila, vertebrate
species exhibit a diversiﬁcation of TLRs up to 12 different transmembrane
proteins, allowing the detection of a wide range of ligands. In combina-
tion and in cooperation with other pathogen recognition receptors, TLRs
precisely exert the function of pathogen recognition, which was
postulated by Charles Janewaymore than 20 years ago [34]. As conserved
germline-encoded pattern recognition receptors, TLRs empower cells
of the innate immune system to reliably differentiate “self” from “nonself”
patterns through detection of conserved microbial PAMPs. The
recognized patterns are unique to microbes and essential products of
their metabolism, so that mutations cannot readily render these
organisms undetectable by TLRs. Finally, the interactions between
PAMPs with TLRs are perceived as signatures of infection and conse-
quently induce an immunological response.
3.1. TLR ligands
TLRs efﬁciently recognize distinct components of various pathogens
through direct or adaptor-mediated binding (see Table 1): TLR1, TLR2
and TLR6 recognize cell wall components of gram-positive bacteria
such as peptidoglycan, N-acyl lipoproteins or lipoteichoic acid. TLR3
and TLR7 are activated by double- or single-stranded RNA, indicating
viral infection, and TLR9 senses unmethylated CpG dinucleotides, a
characteristic feature of bacterial and viral pathogens. TLR4 recognizes
distinct components of lipopolysaccharide (LPS), a cell wall component
of all gram-negative bacteria that consists of a lipophilic region (“lipid
A”), a covalently linked hydrophilic oligosaccharide and a polysaccha-
ride chain termed O-polysaccharide [35,36]. Lipid A constitutes the bio-
logically active compound of LPS, whereas the presence (“smooth” LPS)
or absence (“rough” LPS) of O-polysaccharide varies depending on
the microbial source of LPS and determines the need for additional
adaptor molecules for TLR4 activation [36,37].
Importantly, most TLRs may be activated by diverse ligands,
which often do not share any obvious structural similarities. It is
therefore believed that TLRs may have a wide ligand spectrum that
possibly includes patterns not derived from pathogens [38,39]. This
concept is exempliﬁed by hyaluronic acid, a major component
of the extracellular matrix in virtually all organs. In its physiological,
unfragmented form (Mw>1000 kDa), hyaluronan is biologically
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effects. Following modulation by hyaluronidases and reactive
oxygen species (ROS) during tissue injury, the emerging small
molecular weight fragments (Mw~100–250 kDa) stimulate inﬂam-
matory and wound healing responses through TLR4 and TLR2 on
immune cells [40–44]. HMGB1 is another postulated endogenous
TLR ligand that contributes to inﬂammation in various models of
injury via signaling through TLR2, TLR4 and RAGE on inﬂammatory
cells [25,45]. This abundantly expressed nucleoprotein can be
secreted by activated immune cells or passively released from
necrotic cells, but is retained within cells undergoing apoptosis,
which may account for the virtual lack of inﬂammation in response
to programmed cell death [45,46].
The detection of DAMPs empowers the immune system to
sense tissue damage or danger even in the absence of infection, mostly
mediated through interactions with TLR2 or TLR4, thus sharing receptors
with their PAMPcounterparts [41,47]. Others, such asATP and its receptor
P2X7, cooperate with other inﬂammatory stimuli to induce activation of
the inﬂammasome (see also the chapter on the role of the inﬂammasome
in ﬁbrosis by W. Mehal in this issue). It needs to be noted, however, that
the bona ﬁdeDAMP properties of several candidate molecules remain yet
to be conﬁrmed due to limitations that are inherent to the methodology
employed in this ﬁeld of research: recombinant molecules used
in experimental studies are commonly derived from bacterial systems,
and contamination with bacterial components may account for some of
the observed proinﬂammatory effects. HMGB1 was originally described
as a direct TLR2/4 activator, yet an intrinsic proinﬂammatory activity
was not conﬁrmed in more recent studies [48]. Instead, HMGB1 appears
to amplify the inﬂammatory response to different TLR agonists, as dem-
onstrated by the increased production of tumor necrosis factor (TNF) in
monocytes after stimulation with HMGB1 and LPS in comparison to LPS
alone [49,50], as well as impaired TLR3, TLR7 and TLR9 activation in
vivo in the absence of HMGB1 [51]. Furthermore, the biological properties
of the HMGB1molecule may depend on the redox status of critical cyste-
ine residues, which is largely determined by the wound microenviron-
ment and the mode of HMGB1 release [52]. Future studies employing
clean genetic inactivation methods will help circumvent some of these
limitations and provide clearer insights into the contribution of
individual DAMP candidates to disease processes.Table 1
Toll-like receptors and their respective ligands.
TLR PAMP ligands DAMP ligands References
TLR1 Triacyl lipoproteins [223]
TLR2 Peptidoglycan,
lipoproteins,
zymosan, lipoteichoic
acid, virus envelope
proteins (CMV, HSV1)
Heat shock proteins,
hyaluronan, HMGB1
[37,43,176,224–228]
TLR3 Double-stranded RNA
(dsRNA), poly-(I:C)
[229]
TLR4 Lipopolysaccharide,
taxol, mannan, RSV
fusion protein
Heat shock proteins,
HMGB1, heparin sulfate,
hyaluronic acid,
glycoinositolphospholipids,
ﬁbrinogen
[31,37,43,230–234]
TLR5 Flagellin [235]
TLR6 Diacyl lipopeptides,
lipoteichoic acid
[236]
TLR7 Single-stranded RNA
(ssRNA),
imidazoquinoline
[237–239]
TLR8 Single-stranded RNA
(ssRNA)
[237]
TLR9 Non-methylated CpG Chromatin–IgG complexes [240,241]
TLR10 Unknown
TLR11 Uropathogenic
bacteria
[242]
TLR12 UnknownBeyond ligand speciﬁcity, TLR diversiﬁcation extends to the
subcellular localization of the respective receptor molecules: TLR 1, 2,
4, 5, 6 and 10 are cell surface receptors, whereas TLR 3, 7, 8 and 9 are
localized in the endosome. The differential distribution contributes to
optimal recognition of their respective ligands, as many of the patterns
that activate endosomal TLRs –mostly pathogenic DNA and RNA – enter
through this cellular compartment. In addition, the restriction of TLRs to
speciﬁc cellular compartments may reduce the risk for exposure to
endogenous molecules under physiologic conditions. Finally, the
temporal and spatial patterns of TLR expression emerge as a highly
efﬁcient “response network”, which orchestrates the function of the
involved inﬂammatory and resident cell populations into a coordinated
immune response following tissue injury [53,54].3.2. TLR signaling
Although individual TLRs recognize distinct ligands, the mecha-
nisms of TLR activation and signal transduction are highly conserved
(see Fig. 2). Ligand binding occurs via leucin-rich repeats (LRRs) of
extracellular TLR domains and triggers signal transduction pathways
through interaction of Toll/interleukin-1 receptor (TIR) domains on
the intracellular side with conserved adaptor molecules (reviewed in
[55]). TLR4 signals as a homodimer, but requires the presence of multi-
ple other proteins, including MD-2 and CD14 on macrophages and
RP105 on B cells, to activate downstream signaling in response to LPS.
In contrast to TLR4, TLR2 forms heterodimers with either TLR1 or
TLR6 to recognize components of gram-positive bacteria. TLRs signal
through two upstream signaling molecules, myeloid differentiation
factor 88 (MyD88) or Toll-interleukin-1R domain-containing adaptor
inducing interferon-b (Trif), explaining the similarity of downstream
effects after activation of different TLRs. MyD88 is the adaptor for all
TLRs except for TLR3 which exclusively signals through Trif. TLR4
signals through both MyD88 and Trif. MyD88 and Trif in turn trigger
multiple proinﬂammatory signaling pathways including NF-κB, JNK/
AP1, ERK and p38, and also induce a potent activation of the interferon
pathway through Interferon-regulatory factors (IRFs) [56–58].
TLR activation also triggers regulatory feedback loops, whichmostly
result in a subsequent hyporesponsiveness towards exposure to their
respective ligands, called “TLR tolerance”. This negative regulation
of TLR activity is mediated by a plethora of molecular mechanisms in-
cluding interference with ligand binding, TLR downregulation and deg-
radation, inhibition of downstream signaling, alterations of target
structures through chromatin remodeling, and histone modiﬁcation
(reviewed in [59] and [60]). Due to the use of common signaling cas-
cades, the activation of regulatory pathways through one TLR can lead
to decreased responsiveness of other TLRs, termed “crosstolerance”
[61].4. TLR responsive cell types in wound healing
Cells of the innate immune system constitute the “ﬁrst line of
defense” in response to tissue injury. This groupof cells consists of tissue
resident sentinel cells – mast cells, phagocytes and dendritic cells – as
well as circulating cells: neutrophils, basophils, eosinophils, natural kill-
er (NK) cells, and γδ T cells. In contrast to the effector cells of the adap-
tive immune system, which use highly speciﬁc, randomly generated
antigen receptors to recognize target epitopes, cells of the innate im-
mune system carry germ-line encoded and evolutionarily conserved re-
ceptors (such as the TLRs) for pattern recognition. Other non-myeloid
effector cells of the wound healing response, including epithelial and
endothelial cells, vascular smooth muscle cells and ﬁbroblasts also ex-
press TLRs, andmodulation of TLR signaling in these cell populations af-
fects tissue regeneration [62–64]. In this section, we focus on
TLR-expressing cell types that play a role in wound healing processes.
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Fig. 2. Toll-like receptor signaling as exempliﬁed by TLR4. Toll-like receptors bind to
endogenous and exogenous ligands that indicate tissue injury or infection. Upon stim-
ulation, TLRs activate adaptor molecules (MyD88, Trif), which trigger conserved signal-
ing pathways culminating in a “danger response”, consisting of the induction of
inﬂammatory and anti-viral genes. Other TLR signaling pathways can be reviewed in
[55,57].
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Depending on the organ and the type of injury, wound ﬁbroblasts
originate from tissue-resident, circulating or bone marrow-derived
precursor cells [65–67] and are the main producers of the extracellu-
lar matrix, which replaces the injured or disrupted tissue and consti-
tutes the scaffold for tissue regeneration. The identiﬁcation of TLRs
on ﬁbroblasts in a variety of organs has spurred signiﬁcant interest
into the role of this cell population in inﬂammation in addition to
their well-documented ﬁbrogenic effects. Synovial ﬁbroblasts
isolated from patients with rheumatoid arthritis exhibit a robust
expression of TLRs, particularly TLR3 and TLR4, and respond to
their respective ligands with an increased production of inﬂammato-
ry cytokines [68]. Similar ﬁndings were described for human
intestinal ﬁbroblasts: they express baseline levels of TLR1-9, which
are upregulated in response to LPS or lipoteichoic acid and trigger
downstream signal cascades that culminate in enhanced IL-8 secre-
tion [69]. Likewise, pulmonary ﬁbroblasts are responsive to LPS and
unmethylated CpG DNA via the respective TLRs [70–73]. In the
liver, myoﬁbroblasts are mainly derived from hepatic stellate cells
(HSC), which are normally quiescent and serve as storage cells for
the majority of the body's vitamin A content [74]. Already under
baseline conditions these cells express TLR4, suggesting a sentinel
function for increased levels of LPS. After liver injury, HSCs become
activated — they lose their vitamin A-containing droplets, express
alpha-smooth muscle actin and produce large amounts of collagen
and other extracellular matrix proteins. HSC stimulation with LPS
induces the production of chemokines (MCP-1, MIP-1α, MIP-1β,
RANTES, IP-10) and downregulates Bambi, a repressor of TGFβ
signaling [75]. In a similar fashion, HMGB1 activates hepatic
stellate cells to enhance their inﬂammatory phenotype and to
stimulate ﬁbrogenic gene expression [76]. Unstimulated HSCs
are hyporesponsive to TLR2 ligands, yet pretreatment with TNFα or
IL-1β increases expression of TLR2 and responsiveness to its ligands,
underscoring the role of activated HSCs in the regulation of inﬂam-
mation after tissue injury [77]. Finally, HSCs may respond to
host-derived denatured DNA from apoptotic hepatocytes as well as
non-methylated CpG DNA, a prototypical TLR9-agonistic PAMP
resulting in differentiation processes into ﬁbroblasts via TLR9 activa-
tion [78,79]. Another study did not ﬁnd a role for CpG DNA in
activating HSCs [80] suggesting that TLR9 agonists from apoptotic
cells or TLR9 activation via macrophage-released factors may be
the predominant pathway through which TLR9 promotes ﬁbrosis.
With regard to these ﬁndings, it needs to be acknowledged that
our understanding of ﬁbroblast function and behavior is largely
derived from in vitro experiments, which do not necessarily reﬂect
the situation in vivo in an accurate manner. This is exempliﬁed by
the observation that in vivo-stimulation of HSCs leads to highly cor-
related gene expression patterns across different injury models,
whereas stimulation of isolated HSCs only partially reproduces this
pattern [81]. Future studies using conditional genetic deletion
of TLRs will allow a more precise assessment of TLR function in ﬁbro-
blasts in vivo and circumvent limitations that are inherent to in vitro
approaches.
4.2. TLRs and macrophages
Mononuclear phagocytes arise from at least two distinct precursor
cell populations. The yolk sac is the origin of hematopoietic cells
that migrate into developing organs and form progenitors that
continuously renew tissue resident phagocyte populations [82].
Bone-marrow-derived hematopoietic stem cells give rise to
dendritic cells as well as circulating monocytes in later stages
[83]. After tissue damage, these circulating monocytes are rapidly
recruited from the bloodstream into the site of injury, where they
acquire macrophage phenotypic traits and cooperate with activatedtissue-resident phagocytes in the regulation of inﬂammation, the
destruction of invading pathogens aswell as the processing and presen-
tation of antigens [84–87]. Through phagocytosis of necrotic tissue, deg-
radation of ECM components via matrix-metalloproteinases (MMPs)
and production of anti-inﬂammatory and pro-ﬁbrogenic mediators
(TGFβ, IL10), macrophages also contribute to the restoration of tissue
homeostasis following the initial inﬂammatory phase of wound healing
[88,89]. This crucial role in wound healing is highlighted by profound
effects of depletion or inactivation strategies: in the liver, home of the
largestmacrophage population in the body, genetic or pharmacologic de-
pletion of macrophages ameliorates liver ﬁbrosis in several models of
chronic liver damage, including carbon tetrachloride hepatotoxicity, bile
duct ligation and non-alcoholic steatohepatitis [75,88,90–92]. In the kid-
ney, experimental ﬁbrosis after aminonucleoside nephrosis, renal abla-
tion and unilateral ureteral obstruction is reduced in the absence of
macrophages [93–96], and in the skin, macrophage-depleted mice
exhibit delayed re-epithelialization, diminished collagen deposition,
impaired angiogenesis and decreased cellular proliferation compared to
wild-type control animals [97]. Interestingly, the timing of macrophage
depletion after injury critically affects distinct aspects of the wound
healing response in the skin and liver: macrophage depletion at early
stages of the repair response results in decreased ﬁbrosis in response to
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re-epithelialization and scarring in the skin [88,98]. In striking contrast,
macrophage depletion at late stages of repair increases liver ﬁbrosis
through an MMP13-dependent mechanism [88,89]. The wide spectrum
of macrophage functions reﬂects the diversity and plasticity of this cell
population and has led to the conceptual distinction between M1 and
M2 subtypes with pro- and anti-inﬂammatory properties, respectively.
This distinction, however, still falls short to reﬂect the complexity and
plasticity of these cell populations, and remains a continuously evolving
topic in macrophage biology [99,100].
Many functions of monocytes and macrophages have been linked
to TLR activation. TLR stimulation of bone marrow hematopoietic
stem and progenitor cells induces differentiation into macrophages
and thus supports the rapid generation of immune cells in response
to injury or infection [101]. Circulating monocytes are highly respon-
sive to TLR agonists and activate a wide range of genes after TLR stim-
ulation, including cytokines, chemokines and growth factors, leading
to the recruitment and activation of other cell types after injury
[102,103]. TLR signaling enhances the phagocytic and bactericidal ac-
tivity of macrophages by directing their energy metabolism towards
autophagy and ROS production [104,105]. Cooperative effects be-
tween immune cell populations at the site of injury are highlighted
by the dependence of neutrophils on macrophages to fully exert
their TLR-induced effector functions. Macrophages and dendritic
cells sustain neutrophil function by releasing “survival signals” that
prevent neutrophil apoptosis after LPS challenge; an effect that has
also been observed in the interplay with eosinophils and other cells
of the immune system [106–108]. Conversely, at later stages of
wound healing, macrophages actively suppress further neutrophil re-
cruitment into the wound and thus help to terminate the inﬂamma-
tory response [109].
In contrast to the well-documented effects of global macrophage
deletion or inactivation, the speciﬁc contribution of TLRs on macro-
phages to wound repair and ﬁbrosis is less clear. Proﬁbrogenic effects
of bone-marrow derived macrophages in chronic liver injury are in-
dependent of TLR4 signaling [75], but depend on TLR9-dependent
production of IL-1β by Kupffer cells [80]. In other organs, the contri-
bution of macrophage TLR activation to ﬁbrosis remains elusive as
most experimental studies were carried out in mice with global TLR
deletions. As macrophages exert major functions in the regulation of
inﬂammation and injury in the liver [110–112], the lung [113–116]
and kidney [117–120], it is likely that TLR activation on macrophages
has a more pronounced role in these responses. Their precise role in
tissue ﬁbrosis remains to be deﬁned, and it is possible that differences
in ﬁbrogenic responses between wildtype and TLR-deﬁcient mice
may be indirectly caused by alterations of inﬂammation or injury.
4.3. TLRs and neutrophils
Neutrophils constitute ~70% of all circulating leukocytes and are
usually the ﬁrst cell type to be recruited into the wound in response
to microbial or host-derived stimuli. Except for intracellular TLR3,
human neutrophils express all other TLRs, highlighting their impor-
tance in the induction of an immune response [121]. TLR stimulation
on neutrophils contributes to a prolonged lifespan of this otherwise
short-lived cell population [122]. It also modulates cell surface receptor
expression and initiates degranulation processes aswell as ROS produc-
tion and phagocytosis — all of which add to their potent microbicidal
and proinﬂammatory effects [123]. In addition to these functions, acti-
vated neutrophils release a variety of soluble mediators that regulate
the evolving inﬂammatory response in a context-dependent manner.
Both PAMPs and DAMPs are potent neutrophil activators, however
with differences in neutrophil “ﬁne tuning”. In one study, stimulation
of human neutrophils with LPS or HMGB1 showed an overlapping
upregulation of 95 out of 470 genes; 140 geneswere upregulated exclu-
sively by HMGB1, and 235 by LPS [124]. While this partially reﬂects the“receptor promiscuity” of HMGB1, which extends to other pattern rec-
ognition receptors such as TLR2 and RAGE, it also demonstrates how
the ﬁne composition of the wound microenvironment inﬂuences neu-
trophil activity. Other DAMPs that stimulate neutrophil activation in-
clude mitochondrial DNA fragments (through TLR9 and other
receptors), S100 proteins (through TLR4), as well as ATP and formyl
peptides, which trigger neutrophil recruitment and activation in infec-
tious and sterile models of tissue injury via activation of cell surface re-
ceptors [125–129].
In contrast to the well-established pro-inﬂammatory role of neutro-
phils in various organs in response to injury [130–134], their contribu-
tion to the resolution of inﬂammation and wound healing is less clear.
Cutaneous wounds show accelerated closure in neutrophil-depleted
mice, and heal without scarring in the absence of macrophages and
neutrophils [135,136]. Similarly, in the lung, genetic or pharmacologic
inhibition of neutrophil elastase attenuates bleomycin-induced pulmo-
nary ﬁbrosis [137,138]. Most of these effects, however, may be second-
ary to alterations of the inﬂammatory response rather than evidence of
a direct involvement of neutrophils in ﬁbrosis. Hepatic neutrophils
contribute to injury and ﬁbrogenic wound healing in chronic liver dis-
ease [139,140]; however, liver ﬁbrosis occurs independently of the
presence or activation of neutrophils after bile-duct ligation or chronic
α-naphthylisothiocyanate-induced liver injury [141,142]. Following ac-
tivation, neutrophils undergo apoptosis induced by endogenous or ex-
ogenous triggers and are efﬁciently removed from the wound by
macrophages and dendritic cells, in part mediated by TLR-dependent
mechanisms [143,144].4.4. TLRs and epithelial cells
TLR expression on “classical” immune cells is paramount for the
wound healing response, reﬂecting that the appearance of TLR
ligands indicates a breach in tissue integrity, which necessitates con-
tainment and repair. In contrast, the epithelial linings of the body's
outer and inner surfaces are constantly exposed to PAMPs under
physiologic conditions, particularly in the skin, digestive tract, and
– albeit to a far lesser degree – the lung [145]. These epithelia main-
tain the delicate balance between shielding the organism from
potentially lethal luminal pathogens, while at the same time
providing a surface that tolerates microorganisms and favors the ex-
change of nutrients and gases. Moreover, epithelial organs need to
maintain their ability to detect injury and infection and to control
the inﬂammatory response after injury has occurred — the profound
consequences of excess epithelial inﬂammation are illustrated by
devastating diseases such as Crohn's disease, bronchial asthma or
atopic dermatitis.
Multitudes of reciprocal mechanisms regulate the dynamic inter-
play between the commensal microbiota and the host [146], and
TLRs are important mediators in this interaction with functions
that by far exceed amere sentinel role for invading bacteria. Mice de-
ﬁcient for the TLR adaptor molecule MyD88 exhibit severe morbidity
and mortality upon induction of intestinal injury and inﬂammation
through dextran sodium sulfate (DSS) [147]. While at ﬁrst counter-
intuitive regarding the proinﬂammatory effects of MyD88 activation,
TLR-mediated recognition of commensals was shown to induce the
production of tissue protective factors in epithelial cells, and mice
devoid of a luminal microbiota are more prone to intestinal injury
than control animals [147]. Similar ﬁndings have been made in
other organs such as the liver [148] and the lung [41], where TLR4
deﬁciency or absence of microbiota increases susceptibility to exper-
imental injury, possibly indicating a critical role for baseline TLR ac-
tivity in cellular homeostasis. In a similar fashion, MyD88−/− mice
show a markedly delayed wound healing response after experimen-
tal skin injury with impairments in wound contraction and angio-
genesis [149]. These ﬁndings were more recently corroborated by
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actively suppresses TLR2-induced epithelial inﬂammation in the
skin in a TLR3-dependent manner [150]. While this ﬁnding supports
the idea of a critical role for the microbiota in epithelial homeostasis,
it may also represent a mechanism by which commensals evade
immune responses via TLR crosstolerance. In the lung, MyD88 deﬁ-
ciency attenuates experimentally induced inﬂammation and injury,
but impairs epithelial regeneration and ultimately increases mortal-
ity [41,121,151]. Despite the beneﬁcial role of the microbiota in
epithelial homeostasis, the host needs to prevent and be able to de-
tect bacterial translocation across the epithelium into underlying tis-
sues or the bloodstream. This protection is in part provided by
immune cells in the subepithelial layers of the epidermis and mu-
cous membranes, which constitutively express TLRs and are exposed
to their respective ligands right after the epithelium has been
crossed [146,152,153]. Moreover, TLR expression on the basolateral
cell surface of epithelial cells enables the recognition of bacterial
components and other indicators of an epithelial breach, and the
subsequent induction of inﬂammation even before deeper tissue
layers have been penetrated [154,155].
5. TLRs and organ ﬁbrosis
5.1. Toll-like receptors and liver ﬁbrosis
Chronic hepatic inﬂammation leads to liver ﬁbrosis and is pre-
dominantly caused by chronic viral hepatitis, alcohol abuse and
nonalcoholic steatohepatitis (NASH) in industrialized countries.
Progressive hepatic ﬁbrosis can lead to cirrhosis, hepatocellular
carcinoma and liver failure, and liver transplantation remains the
only curative option for a subset of patients with advanced disease
[156]. Due to its anatomical location, the liver is constantly exposed
to components of gut-derived bacteria entering through the portal
vein, and tolerance towards low levels of LPS and other patterns is
crucial to avoid constant hepatic inﬂammation [157]. This is
reﬂected by the comparatively low expression levels of most TLRs
and signaling adaptor molecules MD-2 and MyD88 in the whole
liver under physiologic conditions [74]. In fact, hepatocytes exhibit
only weak upregulation of inﬂammatory genes after exposure to
LPS, their main function may therefore be its uptake and biliary
secretion rather than the induction of inﬂammation [158,159]. The
ability to respond to tissue damage or pathologic concentrations of
TLR ligands, however, is maintained through baseline TLR expression
on Kupffer cells and hepatic stellate cells, which serve as cellular
sentinels of liver homeostasis. Prolonged or repeated injury to
the liver stimulates a maladaptive interplay of hepatocytes, hepatic
stellate cells (HSCs) and Kupffer cells, ultimately resulting in the
excessive deposition of collagen and other extracellular matrix
proteins in the liver [156,160].
Increased bacterial translocation and elevated levels of circulating
LPS are characteristic for patients with acute and chronic liver
diseases [161,162]. These increases are caused by ultrastructural
alterations of the intestinal mucosa, changes in the composition
of the luminal microbiota, and bacterial overgrowth [163–166]. A
causal involvement of bacteria or bacterial PAMPs in the pathogene-
sis of liver ﬁbrosis was ﬁrst demonstrated in experimental animal
studies in the 1950s and 1960s, and has been extended to a broad
range of models and diseases since then. In rats, a reduction of the
intestinal microbiota through administration of non-absorbable
antibiotics prevents experimental liver ﬁbrosis and cirrhosis
[167,168], an effect that can be reverted by adding LPS to the drink-
ing water [168]. In mice, hepatic ﬁbrogenesis after BDL is strongly
reduced after treatment with a non-absorbable antibiotic cocktail
[75,169]. Likewise, intestinal decontamination protects from liver
ﬁbrosis in response to a choline-deﬁcient diet (a model for NASH)
as well as MDR2 deﬁciency (a genetic model of cholestatic liverdisease) [167,170]. Conversely, increased portal venous concentrations
of bacterial PAMPs including LPS elicited by chemically-induced colitis
strongly enhance experimental hepatic inﬂammation and ﬁbrogenesis
in mice [171].
More recently, the underlying molecular mechanisms, involved-
receptors and signaling pathways were uncovered: TLR4, the receptor
for LPS, is a modulator of hepatic ﬁbrosis, as demonstrated by the
protective effect of TLR4deﬁciency across variousmodels of liver injury,
including bile duct ligation, chronic CCl4 treatment, experimental non-
alcoholic steatohepatitis and alcoholic steatohepatitis [75,92,172,173].
Similar ﬁndingswere demonstrated inmice deﬁcient for the TLR4 bind-
ingmolecules CD14 [174], the LPS co-receptorMD-2 [173] aswell as the
adaptor molecules MyD88 and Trif [75,175], thus conﬁrming a critical
role of TLR4 signaling in inﬂammatory responses in the liver. The cellu-
lar mediators of this TLR4-dependent proﬁbrogenic response are
non-bone marrow-derived cells, with HSCs being the primary effectors
that display increased ﬁbrogenicresponses after LPS treatment in vitro,
and high LPS-responsiveness in vitro and in vivo [75,176]. TLR4 on liver
endothelial cells appears to regulate ﬁbrosis-associated neovessel for-
mation [63] — the biological signiﬁcance of this ﬁnding, however, re-
mains to be conﬁrmed in vivo using conditional ablation of TLR4 in
endothelial cells. Intriguingly, a single nucleotide polymorphism
(SNP) in the human TLR4 gene, which leads to decreased LPS respon-
siveness, has been associatedwith a reduced risk of ﬁbrosis progression
in chronic hepatitis C virus infection [177,178]. Finally, TLR4 activation
through components of the intestinal microbiota links inﬂammation
and carcinogenesis in the chronically injured liver, suggesting that
increased TLR4 signaling promotes progression of chronic liver disease
at various stages [148].
Apart from LPS, TLR4 may also be activated by endogenous ligands
(i.e., heat shock proteins, HMGB1) as demonstrated in a variety of stud-
ies employing different models of acute and chronic liver injury
[76,179–184]. The contribution of individual TLR4 activators, however,
remains a matter of debate, and it is conceivable that both exogenous
and endogenous ligands co-operatively modulate the inﬂammatory
and wound healing response following liver damage. In addition to
TLR4, several studies have demonstrated a critical involvement of
other TLRs in liver disease [126,182,185]. In the setting of chronic hepat-
ic injury, TLR9 is highly expressed on activated stellate cells, and
TLR9-deﬁcient mice are protected from hepatic ﬁbrosis after BDL and
in the CDAAdietmodel of NASH [79,80]. In this context, itwas suggested
that TLR9 expressed on hepatic stellate cells may have a role in the
detection of DNA from apoptotic hepatocytes, and the subsequent HSC
activation to induce ﬁbrosis [79]. TLR2 deﬁciency is associated with de-
creased liver injury and mortality in two models of acute liver damage
[186]. Following the administration of a high-fat diet, liver damage is
exacerbated in the absence of TLR2 [187,188]. By contrast, no difference
in liver injury and only a trend towards decreased liver ﬁbrosis were
reported between TLR2−/− and control mice following BDL [75]. A
recent study reported that liver injury is reduced in TLR2−/− following
BDL or chronic administration of the hepatotoxin carbon tetrachloride.
Interestingly, TLR2-mediated protection from injury is conferred by
TLR2-expressing macrophages of the intestinal lamina propria that
promote increased intestinal permeability after BDL. Consequently,
TLR2−/− exhibit less bacterial translocation and systemic endotoxin
levels following BDL, which may indirectly account for the attenuated
ﬁbrotic response via reduced TLR4 signaling [189]. Together, these stud-
ies suggest a contribution of TLR2 to liver ﬁbrosis, albeit to a smaller ex-
tent than TLR4 and possibly depending on the composition of the gut
microbiome.
While the role of TLRs in various experimental models of hepatic
ﬁbrogenesis has been outlined, their contribution to liver ﬁbrosis
caused by hepatotropic viruses (HBV, HCV) remains widely unknown.
This gap of knowledge regarding some of the most prevalent causes
of human liver disease is largely explained by a lack of suitable
small animal models, but may be overcome with the development
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vestigation of HCV or HBV infection in animal models.
The above studies on the gut microbiome and TLRs in chronic liver
disease not only illustrate the very close relationship between the
liver and the gut reaching far beyond embryonic development, but
also point towards novel strategies to ameliorate ﬁbrogenic responses
in the liver through modulation of the intestinal microbiota or TLR4
signaling (reviewed in [192]). For example, probiotics exert a beneﬁ-
cial inﬂuence on bacterial translocation, circulating endotoxin levels,
liver ﬁbrosis and bacterial infections in preclinical studies and pa-
tients with liver cirrhosis [169,193–195]. Conclusive evidence for a
beneﬁcial effect of the modulation of the intestinal ﬂora on ﬁbrosis
progression or HCC development in humans remains lacking, but
may eventually lead to new treatment strategies in the setting of
chronic liver injury.
5.2. Toll-like receptors and lung ﬁbrosis
Pulmonary ﬁbrosis is a devastating disease in which the replace-
ment of functional lung parenchyma with ﬁbrous tissue progressively
impairs oxygenation and gas exchange, ultimately leading to death
from respiratory failure. Causes of pulmonary ﬁbrosis include
autoimmune disorders, viral infections, radiotherapy, chemotherapy,
graft-versus host disease or aerosolized environmental toxins, yet in
most cases the etiology of the disease remains unknown (“idiopathic
pulmonary ﬁbrosis”, IPF) [181].
Contrasting the traditional belief that the lungs are sterile organs, re-
cent studies have identiﬁed numerous pulmonary commensals that
constitute a “lung microbiome”, which shares distinct similarities with
microbiomes of other organs [196]. Despite a comparatively lowmicro-
bial density in the lung, it is conceivable that these microorganisms ac-
tively partake in pulmonary physiology and in the regulation of
inﬂammation and wound healing after lung injury [196]. In contrast to
the liver, the contribution of TLRs to pulmonary ﬁbrosis and wound
healing is not well deﬁned. Deﬁciency of MyD88, the common adaptor
for all TLRs except TLR3, protects mice from inﬂammation and ﬁbrosis
after treatment with bleomycin (BLM) a glycopeptide antibiotic that
causes pulmonary inﬂammation and ﬁbrosis [151]. Interestingly, the
effect of MyD88 on lung ﬁbrosis is not dependent on TLR2 or TLR4, as
TLR2/4 double knockout mice are not protected from BLM-induced
pulmonary ﬁbrosis [41]. Instead, IL-1R1 triggersMyD88-dependent pro-
motion of lung ﬁbrosis as shown by reduced ﬁbrosis in IL-1R1-deﬁcient
mice that resembles the reduced ﬁbrosis observed in MyD88-deﬁcient
mice (see also the chapter on the role of the inﬂammasome in ﬁbrosis
by W. Mehal in this issue). In fact, two studies demonstrated that TLR4
deﬁciency or pharmacologic TLR4 inhibition exacerbates lung injury
and ﬁbrosis induced by bleomycin and silica, respectively— pointing to-
wards a protective role of TLR4 in these models of lung injury [197,198].
In radiation-induced pulmonary injury, TLR-mediated signals also
protect the lung from ﬁbrosis development as seen by increased
lung ﬁbrosis of TLR2/TLR4-double deﬁcient mice [199]. In a
similar model, it was demonstrated that MyD88-deﬁciency decreases
survival after irradiation, and that surviving MyD88-deﬁcient mice de-
velop increased pulmonary ﬁbrosis in late stages, apparently as
a consequence of persistent inﬂammatory inﬁltrates in the lung [200].
It thus seems that MyD88 deﬁciency alters the pulmonary wound
healing response and ﬁbrogenesis in a highly context-dependent
manner, for reasons that remain to be clariﬁed. In contrast to
TLR2 and TLR4, TLR9 appears to promote lung ﬁbrosis. TLR9 is
present at higher concentrations in surgical lung biopsies from
rapidly progressing IPF patients when compared to biopsies from
slowly progressing patients. Moreover, intranasal CpG promotes ﬁ-
brosis in chimeric mice transplanted with human IPF ﬁbroblasts
[72].
The main effects of TLR2 and TLR4 signaling in the injured lung
are mediated by bone marrow-derived cell populations andepithelial cells — and not by ﬁbroblasts. Inﬂammatory cells from
TLR2/TLR4 double-knockout mice fail to upregulate mediators that
are crucial for the induction and resolution of inﬂammation after
challenge with small molecular weight hyaluronan, and increased
epithelial apoptosis in these animals is held responsible for the in-
creased mortality after bleomycin-induced injury [41]. This may be
the reason why the majority of studies found either no reduction in
pulmonary ﬁbrosis or even increased ﬁbrosis when inhibiting TLR2
and TLR4 signaling in contrast to the ﬁbrosis-reducing effects of
TLR inhibition in organs such as the liver, kidney and skin. Also, it ap-
pears that TLR ligands in the injured lung are not derived from bacteria
but predominantly endogenous ligands, which cooperate with other
endogenous activators of the inﬂammasome, such as uric acid, to attain
a strong inﬂammatory response [201]. A role for DAMPs in lung injury
has also been documented for cigarette smoking, where acute exposure
to cigarette smoke increases pulmonary HSP70 levels and leads to a
TLR4/MyD88 and IL-1R1/MyD88-dependent recruitment of neutrophils
into the lung [202]. The contributions of TLRs to pulmonary injury and
ﬁbrosis, in particularly the role of TLR9, deserve further attention. It is
conceivable that TLR2 and TLR4 stimulation prevent ﬁbrosis, whereas
TLR9 stimulation promotes ﬁbrogenic wound healing in the lung.
Knowledge about the speciﬁc contribution of individual TLRs will not
only allow better understanding of the underlying pathophysiology
but may allow designing targeted therapies, especially in diseases
with unknown etiologies such as IPF.
5.3. Toll-like receptors and kidney ﬁbrosis
Renal ﬁbrosis, characterized by glomerulosclerosis and tubulointer-
stitial ﬁbrosis, is the common terminal end stage of various types of
chronic kidney disease. The development of kidney ﬁbrosis 12and the
parallel destruction of functional kidney parenchyma lead to end-
stage renal failure, a devastating condition that requires dialysis or kid-
ney replacement. Unlike the liver, lung or skin, the kidney is rarely
exposed to bacterial PAMPs. However, levels of endogenous TLR ligands
increase in the injured kidney [203–207]. Moreover, Tamm–Horsfall
protein, a heavily glycosylated protein that is exclusively expressed in
the ascending limb of the Henle's loop and secreted into the urine,
may also act as a TLR4 agonist [208]. There is strong evidence that TLR
signaling regulates the inﬂammatory response to acute kidney injury
as seen by reduced renal inﬂammation and tubular damage in mice
deﬁcient for TLR2, TLR4 or MyD88 after post-ischemic damage
[204,209–212]. In chronic renal injury, TLRs also regulate inﬂammation
and ﬁbrosis, but the contribution to ﬁbrosis appears to bemoderate and
largely mediated by TLR4 and not other TLRs. Similar to other organs,
TLR4 protects the kidney from injury as seen by increased tubular
damage after unilateral ureteral obstruction [213]. Despite increased in-
jury after UUO, TLR4-deﬁcient mice developed considerably less ﬁbro-
sis [213]. Interestingly, TLR4-deﬁcient mice had decreased matrix
metalloproteinase activity and did not showa reduction ofmyoﬁbroblast
accumulation. In vitro, TLR4-deﬁcient primary tubular epithelial cells
and myoﬁbroblasts produced signiﬁcantly less type I collagen mRNA
after TGFβ stimulation than WT cells. These data were conﬁrmed in a
second study, inwhich TLR4 deﬁcientmice exhibited a signiﬁcant reduc-
tion in obstruction-induced α-SMA expression, ﬁbroblast accumulation,
and renal ﬁbrosis [214]. TLR2 is markedly upregulated on tubular and
tubulointerstitial cells in patients with chronic renal injury. In mice
with obstructive nephropathy, renal injury was associated with a
marked upregulation and change in distribution of TLR2 as well as
upregulation of TLR2 ligands Gp96, biglycan, and HMGB1. However,
functional data on the role of TLR2 in renal ﬁbrosis is conﬂicting, with
some studies reporting no inﬂuence on ﬁbrosis [215], one study showing
an effect onmyoﬁbroblast numbers but not long-termﬁbrosis [216], and
a third study showing decreased ﬁbrosis [217]. Together, these studies
suggest at best amoderate promotion of kidney ﬁbrosis by TLR2. Despite
increased expression of TLR9 and TLR9 ligands, TLR9 does not contribute
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regulated neutrophil inﬂux and chemokine production as well as the
number of myoﬁbroblasts, but did not affect long-term ﬁbrosis or injury
development. Deﬁciency of the common adaptor molecule MyD88 sig-
niﬁcantly reducedﬁbrosis after UUO in one study [217], but only showed
a trend towards decreased ﬁbrosis in another study [218]. In summary,
TLRs appear to be critical regulators of acute inﬂammatory responses in
the kidney, which is in contrast to their only moderate contribution to
chronic injury and ﬁbrosis. Additional experimental studies are needed
to improve our understanding of TLRs in the healthy and injured kidney
in order tomake this knowledge applicable to therapeutic interventions.
5.4. Regulation of wound healing and ﬁbrosis in the skin
The skin is an important barrier that shields and protects the
organism from many environmental noxae and pathogens. It is also
the site of a distinct and varied microbiome [145]. Following injury,
the barrier becomes more permeable to bacteria and their products,
resulting in potential exposure to PAMPs or even bacterial superinfec-
tion. Several lines of evidence support a crucial role of TLR-induced sig-
nals in re-epithelization and closure of skin wounds: (i) Topical
application of TLR3 agonist poly(I:C) promotes re-epithelialization,
granulation, and neovascularization required for wound closure in
mice [219]. Notably, topical application of poly-(I:C) accelerates
wound closure in patients with laser plastic surgery. Conversely, mice
that lack TLR3 display delayed wound healing parameters such as
re-epithelialization, granulation formation, and neovascularization
[219]. (ii) Nucleic acids, released by damaged cells in skin wounds,
stimulate TLR7 and TLR9 on inﬁltrating plasmacytoid dendritic cells,
leading to transient production of type I interferons (IFN) [153]. Deﬁ-
ciency of MyD88 and TLR7, or pharmacologic inhibition of TLR7 or
TLR9 inhibits type I IFN production. The presence of dendritic cells
and production of type I IFN are required for re-epithelialization, as
demonstrated by experiments in dendritic cell-depleted and IFN-α/β
receptor-deﬁcientmice, respectively [153]. As demonstrated in another
study, TLR9 knockout mice exhibit a general delay in wound healing
when compared with wild-type mice. Moreover, administration of the
TLR9 agonist CpG ODN promotes the inﬂux of macrophages to the
wound site and increases the production of vascular endothelial growth
factor, expediting neovascularization of the wound bed of mice [220],
and accelerates wound closure in non-human primates [221]. (iii) Exci-
sional skin wounds in MyD88−/− mice heal at a markedly slower rate
than wounds in wild-type MyD88+/+ mice, showing delayed contrac-
tion, decreased and delayed granulation tissue formation, and reduced
density of newly formed blood vessels [149].
While the role for TLRs, in particular TLR3 and TLR9 in wound
healing of the skin is well documented, it is not clear whether TLR4
may contribute to hypertrophic scars (HTS) after skin injury. Expression
of TLR4 and its downstream adaptor myeloid differentiation factor 88
(MyD88) in HTS ﬁbroblasts are signiﬁcantly increased compared with
normal ﬁbroblasts [222]. Moreover, TLR2, TLR3 and TLR4 ligands
strongly induce IFN- and TGFβ-responsive genes in ﬁbroblasts from
normal skin and ﬁbroblasts from patients with systemic sclerosis
[223]. However, no studies have assessed skin ﬁbrosis development in
mice deﬁcient in TLRs or TLR signaling components. It is conceivable
that stimulation of TLR plays an important role in promoting normal
wound healing, but that excessive TLR signaling might contribute to
maladaptive or hypertrophic wound healing and ﬁbrosis.
5.5. Regulation of cardiac remodeling and ﬁbrosis by Toll-like receptors
Cardiac hypertrophy commonly found in response to chronic hyper-
tension is accompanied by an abnormal accumulation of ECM compo-
nents. Cardiac ﬁbrosis increases myocardial stiffness and may thereby
contribute to ventricular dysfunction. TLR2 promotes wound healing
and ﬁbrosis and may thus contribute to some complications after injuryinduced bymyocardial infarction.While infarct size and degree of inﬂam-
matory cell inﬁltrationwere similar inwild-type andTLR2-deﬁcientmice,
myocardial ﬁbrosis in the non-infarct areas was signiﬁcantly reduced
[224]. Moreover, left ventricular dimensions at end diastolewere small-
er, and fractional shortening as well as survival were higher in
TLR2-deﬁcient mice in comparison to wild-type animals. However, an-
other study suggested that TLR2 deﬁciency results in left ventricular di-
lation due to reduced collagen and decorin deposition in the infarct scar
[225]. Interpretation of the latter study needs to be performed carefully
as wild-type and TLR2-deﬁcient mice did not appear in an identical ge-
netic background. TLR4 deﬁciency improves left ventricular function
and improves remodeling by decreasing atrial natriuretic factor,
total collagen and cardiac hypertrophy after myocardial infarction
when compared with WT-MI mice. These changes resulted in signif-
icantly improved survival of TLR4-deﬁcient mice compared with
WT-MI mice [226,227]. MyD88-deﬁcient mice were protected from
cardiac ﬁbrosis induced by complete Freund's adjuvant (CFA) or
MyHC-alpha/CFA-mediated myocarditis [228]. In this study, ﬁbrosis
depended on MyD88 expression in bone marrow-dependent ﬁbro-
blasts. Similar results were found in a study employing aortic banding
as a model of cardiac hypertrophy, where adenovirally delivered
dominant-negative MyD88 signiﬁcantly reduced cardiac hypertrophy,
cardiomyocyte apoptosis and cardiac ﬁbrosis, and improved cardiac
function [229]. Together, these studies suggest that TLR2 and TLR4, via
their common adaptor MyD88, negatively affect remodeling, cardiac
function and ﬁbrosis development after cardiac injury.
6. Summary and outlook
The discovery of TLRs as key activators of innate immunity has
fundamentally changed our understanding of how organisms protect
themselves from infection and survive in the omnipresence of poten-
tially life-threatening microbes. A growing body of evidence on the
involvement of TLRs in tissue injury greatly extends this understand-
ing beyond innate immunity, and provides important insights into
the body's responses to danger. TLRs act as gatekeepers for several
highly efﬁcient response systems that regulate tissue homeostasis
and protect the host after acute injury, but may also trigger maladap-
tive responses if the damaging stimulus cannot be eliminated.
From a medical point of view, this knowledge is of exceptional
interest as it may be used to design new strategies for therapeutic
interventions. Yet, despite signiﬁcant advances in this ﬁeld of re-
search, several very important questions remain unanswered and
need to be resolved before these insights can be translated into clin-
ical practice. Conﬂicting roles of TLRs in different organs and differ-
ent modes of tissue injury make it virtually impossible to outline
distinct greater functions for individual TLRs in wound healing re-
sponses. One explanation for the observed variability may be the
differential contribution of endogenous and exogenous ligands to
TLR activation, which likely depends on the anatomical localization
and the related exposure to microbes, as well as the type of injury
and the physicochemical properties of the emerging wound. Sec-
ondly, we are at best beginning to understand the complex recipro-
cal interactions between the host and his commensal microbiota,
which are in part regulated by TLRs and profoundly inﬂuence the
host's metabolism and overall welfare. Manipulations of this deli-
cate interplay may have adverse long-term side effects that could
exceed the beneﬁts. Inevitably, both alterations of the resident
microbiota and interference with immune regulatory mechanisms
carry the risk of infectious complications. Finally, based on their
role in sterile tissue injury, it is also conceivable that TLRs may ex-
hibit roles in tissue homeostasis and physiology, which are not
known at this point but crucial to the integrity of tissues even in
the absence of damage or infection.
A scientiﬁcally sound and responsible approach to these problems
requires a continuous effort to analyze TLR biology, including the
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with the help of clean genetic models, such as conditional knock-in and
knock-out approaches. Together with an extended understanding of the
precise role of TLRs in homeostasis andwound healing, wewill undoubt-
edly be able to identify new therapeutic targets for the treatment of acute
and chronic diseases and their maladaptive consequences.References
[1] D.A. Kimbrell, B. Beutler, The evolution and genetics of innate immunity, Nat.
Rev. Genet. 2 (2001) 256–267.
[2] J.A. Hoffmann, J.M. Reichhart, Drosophila innate immunity: an evolutionary per-
spective, Nat. Immunol. 3 (2002) 121–126.
[3] S.I. Grivennikov, F.R. Greten, M. Karin, Immunity, inﬂammation, and cancer, Cell
140 (2010) 883–899.
[4] T. Luedde, R.F. Schwabe, Nf-Kappab in the liver—linking injury, ﬁbrosis and
hepatocellular carcinoma, Nat. Rev. Gastroenterol. Hepatol. 8 (2011) 108–118.
[5] J. Kluwe, A. Mencin, R.F. Schwabe, Toll-like receptors, wound healing, and
carcinogenesis, J. Mol. Med. (Berl.) 87 (2009) 125–138.
[6] R. Medzhitov, Origin and physiological roles of inﬂammation, Nature 454 (2008)
428–435.
[7] T.A. Wynn, T.R. Ramalingam, Mechanisms of ﬁbrosis: therapeutic translation for
ﬁbrotic disease, Nat. Med. 18 (2012) 1028–1040.
[8] M.A. Cunningham, P. Romas, P. Hutchinson, S.R. Holdsworth, P.G. Tipping, Tissue
factor and factor VIIa receptor/ligand interactions induce proinﬂammatory in
macrophages, Blood 94 (1999) 3413–3420.
[9] K. Johnson, Y. Choi, E. DeGroot, I. Samuels, A. Creasey, L. Aarden, Potential
mechanisms for a proinﬂammatory vascular cytokine response to coagulation
activation, J. Immunol. 160 (1998) 5130–5135.
[10] G. Demetz, I. Seitz, A. Stein, B. Steppich, P. Groha, R. Brandl, A. Schomig, I. Ott,
Tissue factor–factor VIIa complex induces cytokine expression in coronary
artery smooth muscle cells, Atherosclerosis 212 (2010) 466–471.
[11] C.J. Scotton, M.A. Krupiczojc, M. Konigshoff, P.F. Mercer, Y.C. Lee, N. Kaminski,
J. Morser, J.M. Post, T.M. Maher, A.G. Nicholson, J.D. Moffatt, G.J. Laurent, C.K.
Derian, O. Eickelberg, R.C. Chambers, Increased local expression of coagulation
factor X contributes to the ﬁbrotic response in human and murine lung injury,
J. Clin. Invest. 119 (2009) 2550–2563.
[12] S.R. Steinhubl, Platelets as mediators of inﬂammation, Hematol. Oncol. Clin.
North Am. 21 (2007) 115–121.
[13] C. Dees, A. Akhmetshina, P. Zerr, N. Reich, K. Palumbo, A. Horn, A. Jungel, C.
Beyer, G. Kronke, J. Zwerina, R. Reiter, N. Alenina, L. Maroteaux, S. Gay, G.
Schett, O. Distler, J.H. Distler, Platelet-derived serotonin links vascular disease
and tissue ﬁbrosis, J. Exp. Med. 208 (2011) 961–972.
[14] A.B. Roberts, M.B. Sporn, R.K. Assoian, J.M. Smith, N.S. Roche, L.M. Wakeﬁeld, U.I.
Heine, L.A. Liotta, V. Falanga, J.H. Kehrl, et al., Transforming growth factor type beta:
rapid inductionofﬁbrosis and angiogenesis in vivo and stimulationof collagen forma-
tion in vitro, Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 4167–4171.
[15] H. Kono, K.L. Rock, How dying cells alert the immune system to danger, Nat. Rev.
Immunol. 8 (2008) 279–289.
[16] M.E. Bianchi, DAMPS, PAMPs and alarmins: all we need to know about danger,
J. Leukoc. Biol. 81 (2007) 1–5.
[17] G.Y. Chen, G. Nunez, Sterile inﬂammation: sensing and reacting to damage,
Nat. Rev. Immunol. 10 (2010) 826–837.
[18] D.E. Discher, P. Janmey, Y.L. Wang, Tissue cells feel and respond to the stiffness
of their substrate, Science 310 (2005) 1139–1143.
[19] R.G. Wells, The role of matrix stiffness in regulating cell behavior, Hepatology 47
(2008) 1394–1400.
[20] A.L. Olsen, S.A. Bloomer, E.P. Chan, M.D. Gaca, P.C. Georges, B. Sackey, M. Uemura,
P.A. Janmey, R.G. Wells, Hepatic stellate cells require a stiff environment for
myoﬁbroblastic differentiation, Am. J. Physiol. Gastrointest. Liver Physiol. 301
(2011) G110–G118.
[21] S. Ahrens, S. Zelenay, D. Sancho, P. Hanc, S. Kjaer, C. Feest, G. Fletcher, C. Durkin, A.
Postigo, M. Skehel, F. Batista, B. Thompson, M. Way, C. Reis e Sousa, O. Schulz,
F-Actin is an evolutionarily conserved damage-associated molecular pattern recog-
nized by Dngr-1, a receptor for dead cells, Immunity 36 (2012) 635–645.
[22] D. Jiang, J. Liang, P.W. Noble, Hyaluronan in tissue injury and repair, Annu. Rev.
Cell Dev. Biol. 23 (2007) 435–461.
[23] Y. Shi, J.E. Evans, K.L. Rock, Molecular identiﬁcation of a danger signal that alerts
the immune system to dying cells, Nature 425 (2003) 516–521.
[24] M.A. Hofmann, S. Drury, C. Fu, W. Qu, A. Taguchi, Y. Lu, C. Avila, N. Kambham, A.
Bierhaus, P. Nawroth, M.F. Neurath, T. Slattery, D. Beach, J. McClary, M. Nagashima,
J. Morser, D. Stern, A.M. Schmidt, Ragemediates a novel proinﬂammatory axis: a cen-
tral cell surface receptor for S100/calgranulin polypeptides, Cell 97 (1999) 889–901.
[25] M.T. Lotze, K.J. Tracey, High-mobility group box 1 protein (Hmgb1): nuclear weapon
in the immune arsenal, Nat. Rev. Immunol. 5 (2005) 331–342.
[26] S. Mariathasan, D.S. Weiss, K. Newton, J. McBride, K. O'Rourke, M. Roose-Girma, W.P.
Lee, Y.Weinrauch, D.M.Monack, V.M. Dixit, Cryopyrin activates the inﬂammasome in
response to toxins and ATP, Nature 440 (2006) 228–232.
[27] P. Matzinger, The danger model: a renewed sense of self, Science 296 (2002)
301–305.
[28] R. Lotﬁ, J. Eisenbacher, G. Solgi, K. Fuchs, T. Yildiz, C. Nienhaus, M.T. Rojewski, H.
Schrezenmeier, Human mesenchymal stem cells respond to native but not oxidizeddamage associated molecular pattern molecules from necrotic (tumor) material,
Eur. J. Immunol. 41 (2011) 2021–2028.
[29] S. Meran, D. Thomas, P. Stephens, J. Martin, T. Bowen, A. Phillips, R. Steadman,
Involvement of hyaluronan in regulation of ﬁbroblast phenotype, J. Biol. Chem.
282 (2007) 25687–25697.
[30] K.V. Anderson, L. Bokla, C. Nusslein-Volhard, Establishment of dorsal-ventral
polarity in the Drosophila embryo: the induction of polarity by the toll gene
product, Cell 42 (1985) 791–798.
[31] B. Lemaitre, E. Nicolas, L. Michaut, J.M. Reichhart, J.A. Hoffmann, The
dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent
antifungal response in Drosophila adults, Cell 86 (1996) 973–983.
[32] R. Medzhitov, P. Preston-Hurlburt, C.A. Janeway Jr., A human homologue of the
Drosophila Toll protein signals activation of adaptive immunity, Nature 388
(1997) 394–397.
[33] S. Rutschmann, A. Kilinc, D. Ferrandon, Cutting edge: the Toll pathway is
required for resistance to gram-positive bacterial infections in Drosophila,
J. Immunol. 168 (2002) 1542–1546.
[34] C.A. Janeway Jr., Approaching the asymptote? Evolution and revolution in
immunology, Cold Spring Harb. Symp. Quant. Biol. 54 (Pt 1) (1989) 1–13.
[35] A. Poltorak, X. He, I. Smirnova, M.Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E.
Alejos, M. Silva, C. Galanos, M. Freudenberg, P. Ricciardi-Castagnoli, B. Layton,
B. Beutler, Defective LPS signaling in C3H/HeJ and C57BL/10ScCR mice: muta-
tions in TLR4 gene, Science 282 (1998) 2085–2088.
[36] C. Alexander, E.T. Rietschel, Bacterial lipopolysaccharides and innate immunity,
J. Endotoxin Res. 7 (2001) 167–202.
[37] Z. Jiang, P. Georgel, X. Du, L. Shamel, S. Sovath, S.Mudd,M. Huber, C. Kalis, S. Keck, C.
Galanos, M. Freudenberg, B. Beutler, Cd14 is required for Myd88-independent Lps
signaling, Nat. Immunol. 6 (2005) 565–570.
[38] J.H. Han, S. Akira, K. Calame, B. Beutler, E. Selsing, T. Imanishi-Kari, Class switch
recombination and somatic hypermutation in early mouse B cells are mediated
by B cell and Toll-like receptors, Immunity 27 (2007) 64–75.
[39] B. Beutler, Neo-ligands for innate immune receptors and the etiology of sterile
inﬂammatory disease, Immunol. Rev. 220 (2007) 113–128.
[40] D. Jiang, J. Liang, P.W. Noble, Hyaluronan as an immune regulator in human
diseases, Physiol. Rev. 91 (2011) 221–264.
[41] D. Jiang, J. Liang, J. Fan, S. Yu, S. Chen, Y. Luo, G.D. Prestwich, M.M. Mascarenhas,
H.G. Garg, D.A. Quinn, R.J. Homer, D.R. Goldstein, R. Bucala, P.J. Lee, R. Medzhitov,
P.W. Noble, Regulation of lung injury and repair by Toll-like receptors and
hyaluronan, Nat. Med. 11 (2005) 1173–1179.
[42] C.M. McKee, M.B. Penno, M. Cowman, M.D. Burdick, R.M. Strieter, C. Bao, P.W. Noble,
Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macro-
phages. the role of HA size and CD44, J. Clin. Invest. 98 (1996) 2403–2413.
[43] K.A. Scheibner, M.A. Lutz, S. Boodoo, M.J. Fenton, J.D. Powell, M.R. Horton,
Hyaluronan fragments act as an endogenous danger signal by engaging TLR2,
J. Immunol. 177 (2006) 1272–1281.
[44] P.W. Noble, D. Jiang, Matrix regulation of lung injury, inﬂammation, and repair:
the role of innate immunity, Proc. Am. Thorac. Soc. 3 (2006) 401–404.
[45] G.P. Sims, D.C. Rowe, S.T. Rietdijk, R. Herbst, A.J. Coyle, Hmgb1 and rage in
inﬂammation and cancer, Annu. Rev. Immunol. 28 (2010) 367–388.
[46] P. Scafﬁdi, T. Misteli, M.E. Bianchi, Release of chromatin protein Hmgb1 by
necrotic cells triggers inﬂammation, Nature 418 (2002) 191–195.
[47] M. Yu, H. Wang, A. Ding, D.T. Golenbock, E. Latz, C.J. Czura, M.J. Fenton, K.J.
Tracey, H. Yang, HMGB1 signals through Toll-like receptor (TLR) 4 and TLR2,
Shock 26 (2006) 174–179.
[48] A. Rouhiainen, S. Tumova, L. Valmu, N. Kalkkinen, H. Rauvala, Pivotal advance:
analysis of proinﬂammatory activity of highly puriﬁed eukaryotic recombinant
Hmgb1 (amphoterin), J. Leukoc. Biol. 81 (2007) 49–58.
[49] J.H. Youn, Y.J. Oh, E.S. Kim, J.E. Choi, J.S. Shin, High mobility group box 1 protein
binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14
and enhances lipopolysaccharide-mediated TNF-alpha production in human
monocytes, J. Immunol. 180 (2008) 5067–5074.
[50] H.S. Hreggvidsdottir, A.M. Lundberg, A.C. Aveberger, L. Klevenvall, U. Andersson, H.E.
Harris, High mobility group box protein 1 (Hmgb1)-partner molecule complexes en-
hance cytokine production by signaling through the partner molecule receptor, Mol.
Med. 18 (2012) 224–230.
[51] H. Yanai, T. Ban, Z. Wang, M.K. Choi, T. Kawamura, H. Negishi, M. Nakasato, Y.
Lu, S. Hangai, R. Koshiba, D. Savitsky, L. Ronfani, S. Akira, M.E. Bianchi, K.
Honda, T. Tamura, T. Kodama, T. Taniguchi, Hmgb proteins function as
universal sentinels for nucleic-acid-mediated innate immune responses,
Nature 462 (2009) 99–103.
[52] E. Venereau,M. Casalgrandi,M. Schiraldi, D.J. Antoine, A. Cattaneo, F. DeMarchis, J. Liu,
A. Antonelli, A. Preti, L. Raeli, S.S. Shams, H. Yang, L. Varani, U. Andersson, K.J. Tracey, A.
Bachi, M. Uguccioni, M.E. Bianchi, Mutually exclusive redox forms of Hmgb1 promote
cell recruitment or proinﬂammatory cytokine release, J. Exp. Med. 209 (9) (2012)
1519–1528.
[53] J. Fan, R.S. Frey, A.B. Malik, TLR4 signaling induces TLR2 expression in endothe-
lial cells via neutrophil NADPH oxidase, J. Clin. Invest. 112 (2003) 1234–1243.
[54] E. Latz, D.T. Golenbock, Receptor “cross talk” in innate immunity, J. Clin. Invest. 112
(2003) 1136–1137.
[55] T. Kawai, S. Akira, TLR signaling, Semin. Immunol. 19 (2007) 24–32.
[56] S. Akira, K. Takeda, Toll-like receptor signalling, Nat. Rev. Immunol. 4 (2004)
499–511.
[57] G.M. Barton, R. Medzhitov, Toll-like receptor signaling pathways, Science 300 (2003)
1524–1525.
[58] K. Honda, T. Taniguchi, IRFs: master regulators of signalling by Toll-like receptors and
cytosolic pattern-recognition receptors, Nat. Rev. Immunol. 6 (2006) 644–658.
1014 P. Huebener, R.F. Schwabe / Biochimica et Biophysica Acta 1832 (2013) 1005–1017[59] L.A. O'Neill, When signaling pathways collide: positive and negative regulation
of Toll-Like receptor signal transduction, Immunity 29 (2008) 12–20.
[60] R. Medzhitov, T. Horng, Transcriptional control of the inﬂammatory response,
Nat. Rev. Immunol. 9 (2009) 692–703.
[61] A. Bagchi, E.A. Herrup, H.S. Warren, J. Trigilio, H.S. Shin, C. Valentine, J. Hellman,
MyD88-dependent and MyD88-independent pathways in synergy, priming, and
tolerance between TLR agonists, J. Immunol. 178 (2007) 1164–1171.
[62] K. Grote, H. Schutt, B. Schieffer, Toll-like receptors in angiogenesis, Sci. World J.
11 (2011) 981–991.
[63] K. Jagavelu, C. Routray, U. Shergill, S.P. O'Hara, W. Faubion, V.H. Shah, Endothelial cell
Toll-like receptor 4 regulates ﬁbrosis-associated angiogenesis in the liver, Hepatology
52 (2010) 590–601.
[64] X. Yang, D. Coriolan, V. Murthy, K. Schultz, D.T. Golenbock, D. Beasley,
Proinﬂammatory phenotype of vascular smooth muscle cells: role of efﬁcient
Toll-like receptor 4 signaling, Am. J. Physiol. Heart Circ. Physiol. 289 (2005)
H1069–H1076.
[65] T.A. Wynn, Common and unique mechanisms regulate ﬁbrosis in various
ﬁbroproliferative diseases, J. Clin. Invest. 117 (2007) 524–529.
[66] S. Dulauroy, S.E. Di Carlo, F. Langa, G. Eberl, L. Peduto, Lineage tracing and
genetic ablation of ADAM12(+) perivascular cells identify a major source of
proﬁbrotic cells during acute tissue injury, Nat. Med. 18 (2012) 1262–1270.
[67] J.S. Dufﬁeld, The elusive source of myoﬁbroblasts: problem solved? Nat. Med. 18
(2012) 1178–1180.
[68] M. Pierer, J. Rethage, R. Seibl, R. Lauener, F. Brentano, U. Wagner, H. Hantzschel, B.A.
Michel, R.E. Gay, S. Gay, D. Kyburz, Chemokine secretion of rheumatoid arthritis syno-
vial ﬁbroblasts stimulated by Toll-like receptor 2 ligands, J. Immunol. 172 (2004)
1256–1265.
[69] J.M. Otte, I.M. Rosenberg, D.K. Podolsky, Intestinal myoﬁbroblasts in innate immune
responses of the intestine, Gastroenterology 124 (2003) 1866–1878.
[70] Z. He, Y. Zhu, H. Jiang, Inhibiting Toll-like receptor 4 signaling ameliorates
pulmonary ﬁbrosis during acute lung injury induced by lipopolysaccharide: an
experimental study, Respir. Res. 10 (2009) 126.
[71] Z. He, Y. Zhu, H. Jiang, Toll-like receptor 4mediates lipopolysaccharide-induced colla-
gen secretion by phosphoinositide3-kinase-Akt pathway in ﬁbroblasts during acute
lung injury, J. Recept. Signal Transduct. Res. 29 (2009) 119–125.
[72] G. Trujillo, A. Meneghin, K.R. Flaherty, L.M. Sholl, J.L. Myers, E.A. Kazerooni, B.H.
Gross, S.R. Oak, A.L. Coelho, H. Evanoff, E. Day, G.B. Toews, A.D. Joshi, M.A. Schaller,
B. Waters, G. Jarai, J. Westwick, S.L. Kunkel, F.J. Martinez, C.M. Hogaboam, TLR9
differentiates rapidly from slowly progressing forms of idiopathic pulmonary
ﬁbrosis, Sci. Transl. Med. 2 (2010) 57ra82.
[73] A. Meneghin, E.S. Choi, H.L. Evanoff, S.L. Kunkel, F.J. Martinez, K.R. Flaherty, G.B.
Toews, C.M. Hogaboam, TLR9 is expressed in idiopathic interstitial pneumonia
and its activation promotes in vitro myoﬁbroblast differentiation, Histochem.
Cell Biol. 130 (2008) 979–992.
[74] S.L. Friedman, Hepatic stellate cells: protean, multifunctional, and enigmatic
cells of the liver, Physiol. Rev. 88 (2008) 125–172.
[75] E. Seki, S. De Minicis, C.H. Osterreicher, J. Kluwe, Y. Osawa, D.A. Brenner, R.F.
Schwabe, TLR4 enhances TGF-beta signaling and hepatic ﬁbrosis, Nat. Med. 13
(2007) 1324–1332.
[76] Z. Zhang, C. Lin, L. Peng, Y. Ouyang, Y. Cao, J. Wang, S.L. Friedman, J. Guo, High
mobility group box 1 activates Toll like receptor 4 signaling in hepatic stellate
cells, Life Sci. 91 (2012) (5-6), 207–212.
[77] Y.H. Paik, K.S. Lee, H.J. Lee, K.M. Yang, S.J. Lee, D.K. Lee, K.H. Han, C.Y. Chon, S.I.
Lee, Y.M. Moon, D.A. Brenner, Hepatic stellate cells primed with cytokines
upregulate inﬂammation in response to peptidoglycan or lipoteichoic acid,
Lab. Invest. 86 (2006) 676–686.
[78] A. Watanabe, A. Hashmi, D.A. Gomes, T. Town, A. Badou, R.A. Flavell, W.Z. Mehal,
Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via Toll-like
receptor 9, Hepatology 46 (2007) 1509–1518.
[79] E. Gabele, M. Muhlbauer, C. Dorn, T.S. Weiss, M. Froh, B. Schnabl, R. Wiest, J.
Scholmerich, F. Obermeier, C. Hellerbrand, Role of TLR9 in hepatic stellate cells and
experimental liver ﬁbrosis, Biochem. Biophys. Res. Commun. 376 (2008) 271–276.
[80] K. Miura, Y. Kodama, S. Inokuchi, B. Schnabl, T. Aoyama, H. Ohnishi, J.M. Olefsky,
D.A. Brenner, E. Seki, Toll-like receptor 9 promotes steatohepatitis by induction
of interleukin-1beta in mice, Gastroenterology 139 (2010) 323–334, (e327).
[81] S. De Minicis, E. Seki, H. Uchinami, J. Kluwe, Y. Zhang, D.A. Brenner, R.F. Schwabe,
Gene expression proﬁles during hepatic stellate cell activation in culture and in
vivo, Gastroenterology 132 (2007) 1937–1946.
[82] C. Schulz, E. Gomez Perdiguero, L. Chorro, H. Szabo-Rogers, N. Cagnard, K. Kierdorf,
M. Prinz, B. Wu, S.E. Jacobsen, J.W. Pollard, J. Frampton, K.J. Liu, F. Geissmann, A
lineage ofmyeloid cells independent ofMyb and hematopoietic stem cells, Science
336 (2012) 86–90.
[83] A. Cumano, I. Godin, Ontogeny of the hematopoietic system, Annu. Rev. Immunol. 25
(2007) 745–785.
[84] C. Auffray, M.H. Sieweke, F. Geissmann, Blood monocytes: development,
heterogeneity, and relationship with dendritic cells, Annu. Rev. Immunol. 27
(2009) 669–692.
[85] C. Shi, E.G. Pamer, Monocyte recruitment during infection and inﬂammation, Nat.
Rev. Immunol. 11 (2011) 762–774.
[86] N.V. Serbina, T. Jia, T.M. Hohl, E.G. Pamer, Monocyte-mediated defense against
microbial pathogens, Annu. Rev. Immunol. 26 (2008) 421–452.
[87] F. Geissmann, M.G. Manz, S. Jung, M.H. Sieweke, M. Merad, K. Ley, Development
of monocytes, macrophages, and dendritic cells, Science 327 (2010) 656–661.
[88] J.S. Dufﬁeld, S.J. Forbes, C.M. Constandinou, S. Clay, M. Partolina, S. Vuthoori, S.
Wu, R. Lang, J.P. Iredale, Selective depletion of macrophages reveals distinct,
roles during liver injury and repair, J. Clin. Invest. 115 (2005) 56–65.[89] J.A. Fallowﬁeld, M. Mizuno, T.J. Kendall, C.M. Constandinou, R.C. Benyon, J.S.
Dufﬁeld, J.P. Iredale, Scar-associated macrophages are a major source of hepatic
matrix metalloproteinase-13 and facilitate the resolution of murine hepatic
ﬁbrosis, J. Immunol. 178 (2007) 5288–5295.
[90] C.A. Rivera, B.U. Bradford, K.J. Hunt, Y. Adachi, L.W. Schrum, D.R. Koop, E.R.
Burchardt, R.A. Rippe, R.G. Thurman, Attenuation of Ccl(4)-induced hepatic
ﬁbrosis by Gdcl(3) treatment or dietary glycine, Am. J. Physiol. Gastrointest.
Liver Physiol. 281 (2001) G200–G207.
[91] Y. Toyoda, T. Shida, N. Wakita, Y. Matoba, N. Ozaki, Mitral valve replacement in a
patient with an extensively calciﬁed mitral anulus: report of a case, Surg. Today
28 (1998) 427–429.
[92] C.A. Rivera, P. Adegboyega, N. van Rooijen, A. Tagalicud, M. Allman, M. Wallace,
Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the
pathogenesis of non-alcoholic steatohepatitis, J. Hepatol. 47 (2007) 571–579.
[93] J.R. Diamond, I. Pesek-Diamond, Sublethal X-irradiation during acute puromycin
nephrosis prevents late renal injury: role of macrophages, Am. J. Physiol. 260
(1991) F779–F786.
[94] H. van Goor, M.L. van der Horst, V. Fidler, J. Grond, Glomerular macrophage
modulation affects mesangial expansion in the rat after renal ablation, Lab. In-
vest. 66 (1992) 564–571.
[95] S.A. Sung, S.K. Jo, W.Y. Cho, N.H. Won, H.K. Kim, Reduction of renal ﬁbrosis as a
result of liposome encapsulated clodronate induced macrophage depletion after
unilateral ureteral obstruction in rats, Nephron Exp. Nephrol. 105 (2007) e1–e9.
[96] Y. Machida, K. Kitamoto, Y. Izumi, M. Shiota, J. Uchida, Y. Kira, T. Nakatani, K.
Miura, Renal ﬁbrosis in murine obstructive nephropathy is attenuated by
depletion of monocyte lineage, not dendritic cells, J. Pharmacol. Sci. 114
(2010) 464–473.
[97] R. Mirza, L.A. DiPietro, T.J. Koh, Selective and speciﬁc macrophage ablation is
detrimental to wound healing in mice, Am. J. Pathol. 175 (2009) 2454–2462.
[98] T. Lucas, A. Waisman, R. Ranjan, J. Roes, T. Krieg, W. Muller, A. Roers, S.A. Eming,
Differential roles of macrophages in diverse phases of skin repair, J. Immunol.
184 (2010) 3964–3977.
[99] D.M. Mosser, J.P. Edwards, Exploring the full spectrum of macrophage activation,
Nat. Rev. Immunol. 8 (2008) 958–969.
[100] P.J. Murray, T.A. Wynn, Protective and pathogenic functions of macrophage sub-
sets, Nat. Rev. Immunol. 11 (2011) 723–737.
[101] J. Megias, A. Yanez, S. Moriano, J.E. O'Connor, D. Gozalbo, M.L. Gil, Direct Toll-like
receptor-mediated stimulation of hematopoietic stem and progenitor cells
occurs in vivo and promotes differentiation toward macrophages, Stem Cells
30 (2012) 1486–1495.
[102] C.A. Salkowski, G. Detore, A. Franks, M.C. Falk, S.N. Vogel, Pulmonary and hepatic
gene expression following cecal ligation and puncture: monophosphoryl lipid a
prophylaxis attenuates sepsis-induced cytokine and chemokine expression and
neutrophil inﬁltration, Infect. Immun. 66 (1998) 3569–3578.
[103] Z.M. Wang, C. Liu, R. Dziarski, Chemokines are the main proinﬂammatory
mediators in human monocytes activated by Staphylococcus aureus, peptidogly-
can, and endotoxin, J. Biol. Chem. 275 (2000) 20260–20267.
[104] A.P. West, I.E. Brodsky, C. Rahner, D.K. Woo, H. Erdjument-Bromage, P. Tempst,
M.C. Walsh, Y. Choi, G.S. Shadel, S. Ghosh, TLR signalling augments macrophage
bactericidal activity through mitochondrial ROS, Nature 472 (2011) 476–480.
[105] M.A. Sanjuan, C.P. Dillon, S.W. Tait, S. Moshiach, F. Dorsey, S. Connell, M.
Komatsu, K. Tanaka, J.L. Cleveland, S. Withoff, D.R. Green, Toll-like receptor
signalling in macrophages links the autophagy pathway to phagocytosis, Nature
450 (2007) 1253–1257.
[106] L.R. Prince, L. Allen, E.C. Jones, P.G. Hellewell, S.K. Dower, M.K. Whyte, I. Sabroe,
The role of interleukin-1beta in direct and Toll-like receptor 4-mediated neutro-
phil activation and survival, Am. J. Pathol. 165 (2004) 1819–1826.
[107] S.R. Walmsley, A.S. Cowburn, A. Sobolewski, J. Murray, N. Farahi, I. Sabroe, E.R.
Chilvers, Characterization of the survival effect of tumour necrosis factor-alpha
in human neutrophils, Biochem. Soc. Trans. 32 (2004) 456–460.
[108] J. Meerschaert, W.W. Busse, P.J. Bertics, D.F. Mosher, Cd14(+) cells are necessary
for increased survival of eosinophils in response to lipopolysaccharide, Am. J.
Respir. Cell Mol. Biol. 23 (2000) 780–787.
[109] O. Soehnlein, L. Lindbom, Phagocyte partnership during the onset and resolution
of inﬂammation, Nat. Rev. Immunol. 10 (2010) 427–439.
[110] D.L. Laskin, C.R. Gardner, V.F. Price, D.J. Jollow, Modulation of macrophage func-
tioning abrogates the acute hepatotoxicity of acetaminophen, Hepatology 21
(1995) 1045–1050.
[111] D.R. Koop, B. Klopfenstein, Y. Iimuro, R.G. Thurman, Gadolinium chloride blocks
alcohol-dependent liver toxicity in rats treated chronically with intragastric
alcohol despite the induction of Cyp2e1, Mol. Pharmacol. 51 (1997) 944–950.
[112] Y. Iimuro, M. Yamamoto, H. Kohno, J. Itakura, H. Fujii, Y. Matsumoto, Blockade of liver
macrophages by gadolinium chloride reduces lethality in endotoxemic rats—analysis
of mechanisms of lethality in endotoxemia, J. Leukoc. Biol. 55 (1994) 723–728.
[113] M. Zhao, L.G. Fernandez, A. Doctor, A.K. Sharma, A. Zarbock, C.G. Tribble, I.L.
Kron, V.E. Laubach, Alveolar macrophage activation is a key initiation signal
for acute lung ischemia–reperfusion injury, Am. J. Physiol. Lung Cell. Mol.
Physiol. 291 (2006) L1018–L1026.
[114] J.A. Frank, C.M. Wray, D.F. McAuley, R. Schwendener, M.A. Matthay, Alveolar mac-
rophages contribute to alveolar barrier dysfunction in ventilator-induced lung in-
jury, Am. J. Physiol. Lung Cell. Mol. Physiol. 291 (2006) L1191–L1198.
[115] A. Prakash, K.R. Mesa, K. Wilhelmsen, F. Xu, O.J. Dodd, J. Hellman, Alveolar
macrophages and Toll-like receptor 4 mediate ventilated lung ischemia reperfu-
sion injury in mice, Anesthesiology 117 (4) (2012) 822–835.
[116] K.J. Pendino, T.M. Meidhof, D.E. Heck, J.D. Laskin, D.L. Laskin, Inhibition of
macrophages with gadolinium chloride abrogates ozone-induced pulmonary
1015P. Huebener, R.F. Schwabe / Biochimica et Biophysica Acta 1832 (2013) 1005–1017injury and inﬂammatory mediator production, Am. J. Respir. Cell Mol. Biol. 13
(1995) 125–132.
[117] Y.J. Day, L. Huang, H. Ye, J. Linden, M.D. Okusa, Renal ischemia–reperfusion
injury and adenosine 2a receptor-mediated tissue protection: role of macro-
phages, Am. J. Physiol. Renal Physiol. 288 (2005) F722–F731.
[118] L. Lu, S. Faubel, Z. He, A. Andres Hernando, A. Jani, R. Kedl, C.L. Edelstein, Deple-
tion of macrophages and dendritic cells in ischemic acute kidney injury, Am.
J. Nephrol. 35 (2012) 181–190.
[119] C.P. Carlos, G.E. Mendes, A.R. Miquelin, M.A. Luz, C.G. da Silva, N. van Rooijen,
T.M. Coimbra, E.A. Burdmann, Macrophage depletion attenuates chronic cyclo-
sporine A nephrotoxicity, Transplantation 89 (2010) 1362–1370.
[120] J.S. Dufﬁeld, P.G. Tipping, T. Kipari, J.F. Cailhier, S. Clay, R. Lang, J.V. Bonventre,
J. Hughes, Conditional ablation of macrophages halts progression of crescentic
glomerulonephritis, Am. J. Pathol. 167 (2005) 1207–1219.
[121] F. Hayashi, T.K. Means, A.D. Luster, Toll-like receptors stimulate human neutro-
phil function, Blood 102 (2003) 2660–2669.
[122] E.P. Dick, L.R. Prince, E.C. Prestwich, S.A. Renshaw, M.K. Whyte, I. Sabroe, Path-
ways regulating lipopolysaccharide-induced neutrophil survival revealed by
lentiviral transduction of primary human neutrophils, Immunology 127
(2009) 249–255.
[123] F. Colotta, F. Re, N. Polentarutti, S. Sozzani, A. Mantovani, Modulation of granu-
locyte survival and programmed cell death by cytokines and bacterial products,
Blood 80 (1992) 2012–2020.
[124] J.S. Park, J. Arcaroli, H.K. Yum, H. Yang, H. Wang, K.Y. Yang, K.H. Choe, D.
Strassheim, T.M. Pitts, K.J. Tracey, E. Abraham, Activation of gene expression in
human neutrophils by high mobility group box 1 protein, Am. J. Physiol. Cell
Physiol. 284 (2003) C870–C879.
[125] Q. Zhang, M. Raoof, Y. Chen, Y. Sumi, T. Sursal, W. Junger, K. Brohi, K. Itagaki, C.J.
Hauser, Circulating mitochondrial damps cause inﬂammatory responses to
injury, Nature 464 (2010) 104–107.
[126] P.E. Marques, S.S. Amaral, D.A. Pires, L.L. Nogueira, F.M. Soriani, B.H. Freire
Lima, G.A. Oliveira Lopes, R.C. Russo, T.V. Avila, J.G. Melgaco, A.G. Oliveira,
M.A. Pinto, C.X. Lima, A.M. de Paula, D.C. Cara, M.F. Leite, M.M. Teixeira, G.B.
Menezes, Chemokines and mitochondrial products activate neutrophils to
amplify organ injury during mouse acute liver failure, Hepatology 56 (5)
(2012) 1971–1982.
[127] Q. Zhang, K. Itagaki, C.J. Hauser, Mitochondrial DNA is released by shock and ac-
tivates neutrophils via P38 map kinase, Shock 34 (2010) 55–59.
[128] C. Ryckman, K. Vandal, P. Rouleau, M. Talbot, P.A. Tessier, Proinﬂammatory ac-
tivities of S100: proteins S100a8, S100a9, and S100a8/A9 induce neutrophil che-
motaxis and adhesion, J. Immunol. 170 (2003) 3233–3242.
[129] B. McDonald, K. Pittman, G.B. Menezes, S.A. Hirota, I. Slaba, C.C. Waterhouse, P.L.
Beck, D.A. Muruve, P. Kubes, Intravascular danger signals guide neutrophils to
sites of sterile inﬂammation, Science 330 (2010) 362–366.
[130] J.S. Gujral, A. Farhood, M.L. Bajt, H. Jaeschke, Neutrophils aggravate acute liver
injury during obstructive cholestasis in bile duct-ligated mice, Hepatology 38
(2003) 355–363.
[131] H. Jaeschke, A. Farhood, C.W. Smith, Neutrophils contribute to ischemia/reperfusion
injury in rat liver in vivo, FASEB J. 4 (1990) 3355–3359.
[132] J. Grommes, O. Soehnlein, Contribution of neutrophils to acute lung injury, Mol.
Med. 17 (2011) 293–307.
[133] P.R. Hansen, Role of neutrophils in myocardial ischemia and reperfusion, Circu-
lation 91 (1995) 1872–1885.
[134] K.J. Kelly, W.W. Williams Jr., R.B. Colvin, S.M. Meehan, T.A. Springer, J.C.
Gutierrez-Ramos, J.V. Bonventre, Intercellular adhesion molecule-1-deﬁcient
mice are protected against ischemic renal injury, J. Clin. Invest. 97 (1996)
1056–1063.
[135] J.V. Dovi, L.K. He, L.A. DiPietro, Accelerated wound closure in neutrophil-depleted
mice, J. Leukoc. Biol. 73 (2003) 448–455.
[136] P. Martin, D. D'Souza, J. Martin, R. Grose, L. Cooper, R. Maki, S.R. McKercher,
Wound healing in the PU.1 null mouse—tissue repair is not dependent on
inﬂammatory cells, Curr. Biol. 13 (2003) 1122–1128.
[137] F. Chua, S.E. Dunsmore, P.H. Clingen, S.E. Mutsaers, S.D. Shapiro, A.W. Segal, J. Roes,
G.J. Laurent, Mice lacking neutrophil elastase are resistant to bleomycin-induced
pulmonary ﬁbrosis, Am. J. Pathol. 170 (2007) 65–74.
[138] A. Takemasa, Y. Ishii, T. Fukuda, A neutrophil elastase inhibitor prevents
bleomycin-induced pulmonary ﬁbrosis in mice, Eur. Respir. J. 40 (6) (2012)
1475–1482.
[139] M.M. Zaldivar, K. Pauels, P. vonHundelshausen, M.L. Berres, P. Schmitz, J. Bornemann,
M.A. Kowalska, N. Gassler, K.L. Streetz, R. Weiskirchen, C. Trautwein, C. Weber, H.E.
Wasmuth, Cxc chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experi-
mental liver ﬁbrosis, Hepatology 51 (2010) 1345–1353.
[140] H. Louis, J.L. Van Laethem,W.Wu, E. Quertinmont, C. Degraef, K. Van den Berg, A.
Demols, M. Goldman, O. Le Moine, A. Geerts, J. Deviere, Interleukin-10 controls
neutrophilic inﬁltration, hepatocyte proliferation, and liver ﬁbrosis induced by
carbon tetrachloride in mice, Hepatology 28 (1998) 1607–1615.
[141] J.M. Saito, M.K. Bostick, C.B. Campe, J. Xu, J.J. Maher, Inﬁltrating neutrophils in
bile duct-ligated livers do not promote hepatic ﬁbrosis, Hepatol. Res. 25
(2003) 180–191.
[142] J. Xu, G. Lee, H. Wang, J.M. Vierling, J.J. Maher, Limited role for Cxc chemokines in
the pathogenesis of alpha-naphthylisothiocyanate-induced liver injury, Am. J.
Physiol. Gastrointest. Liver Physiol. 287 (2004) G734–G741.
[143] J.S. Savill, A.H. Wyllie, J.E. Henson, M.J. Walport, P.M. Henson, C. Haslett, Macro-
phage phagocytosis of aging neutrophils in inﬂammation. Programmed cell
death in the neutrophil leads to its recognition by macrophages, J. Clin. Invest.
83 (1989) 865–875.[144] P. Rovere, G. Peri, F. Fazzini, B. Bottazzi, A. Doni, A. Bondanza, V.S. Zimmermann,
C. Garlanda, U. Fascio, M.G. Sabbadini, C. Rugarli, A. Mantovani, A.A. Manfredi,
The long pentraxin Ptx3 binds to apoptotic cells and regulates their clearance
by antigen-presenting dendritic cells, Blood 96 (2000) 4300–4306.
[145] C. Human Microbiome Project, Structure, function and diversity of the healthy
human microbiome, Nature 486 (2012) 207–214.
[146] L.V. Hooper, D.R. Littman, A.J. Macpherson, Interactions between the microbiota
and the immune system, Science 336 (2012) 1268–1273.
[147] S. Rakoff-Nahoum, J. Paglino, F. Eslami-Varzaneh, S. Edberg, R. Medzhitov,
Recognition of commensal microﬂora by Toll-like receptors is required for intes-
tinal homeostasis, Cell 118 (2004) 229–241.
[148] D.H.Dapito, A.Mencin, G.Y. Gwak, J.P. Pradere,M.K. Jang, I.Mederacke, J.M. Caviglia, H.
Khiabanian, A. Adeyemi, R. Bataller, J.H. Lefkowitch,M. Bower, R. Friedman, R.B. Sartor,
R. Rabadan, R.F. Schwabe, Promotion of hepatocellular carcinoma by the intestinal
microbiota and TLR4, Cancer Cell 21 (2012) 504–516.
[149] L. Macedo, G. Pinhal-Enﬁeld, V. Alshits, G. Elson, B.N. Cronstein, S.J. Leibovich,
Wound healing is impaired in Myd88-deﬁcient mice: a role for Myd88 in the
regulation of wound healing by adenosine A2a receptors, Am. J. Pathol. 171
(2007) 1774–1788.
[150] Y. Lai, A. Di Nardo, T. Nakatsuji, A. Leichtle, Y. Yang, A.L. Cogen, Z.R. Wu, L.V.
Hooper, R.R. Schmidt, S. von Aulock, K.A. Radek, C.M. Huang, A.F. Ryan, R.L.
Gallo, Commensal bacteria regulate Toll-like receptor 3-dependent inﬂamma-
tion after skin injury, Nat. Med. 15 (2009) 1377–1382.
[151] P. Gasse, C. Mary, I. Guenon, N. Noulin, S. Charron, S. Schnyder-Candrian, B.
Schnyder, S. Akira, V.F. Quesniaux, V. Lagente, B. Ryffel, I. Couillin, Il-1r1/Myd88
signaling and the inﬂammasome are essential in pulmonary inﬂammation and
ﬁbrosis in mice, J. Clin. Invest. 117 (2007) 3786–3799.
[152] M.A. Kinnebrew, E.G. Pamer, Innate immune signaling in defense against
intestinal microbes, Immunol. Rev. 245 (2012) 113–131.
[153] J. Gregorio, S. Meller, C. Conrad, A. Di Nardo, B. Homey, A. Lauerma, N. Arai, R.L.
Gallo, J. Digiovanni, M. Gilliet, Plasmacytoid dendritic cells sense skin injury and
promote wound healing through type I interferons, J. Exp. Med. 207 (2010)
2921–2930.
[154] A.T. Gewirtz, T.A. Navas, S. Lyons, P.J. Godowski, J.L. Madara, Cutting edge:
bacterial ﬂagellin activates basolaterally expressed TLR5 to induce epithelial
proinﬂammatory gene expression, J. Immunol. 167 (2001) 1882–1885.
[155] M.T. Abreu, Toll-like receptor signalling in the intestinal epithelium: how
bacterial recognition shapes intestinal function, Nat. Rev. Immunol. 10 (2010)
131–144.
[156] R. Bataller, D.A. Brenner, Liver ﬁbrosis, J. Clin. Invest. 115 (2005) 209–218.
[157] R.F. Schwabe, E. Seki, D.A. Brenner, Toll-like receptor signaling in the liver,
Gastroenterology 130 (2006) 1886–1900.
[158] T. Matsumura, T. Degawa, T. Takii, H. Hayashi, T. Okamoto, J. Inoue, K. Onozaki,
Traf6-Nf-Kappab pathway is essential for interleukin-1-induced TLR2 expres-
sion and its functional response to TLR2 ligand in murine hepatocytes, Immu-
nology 109 (2003) 127–136.
[159] Y. Mimura, S. Sakisaka, M. Harada, M. Sata, K. Tanikawa, Role of hepatocytes in
direct clearance of lipopolysaccharide in rats, Gastroenterology 109 (1995)
1969–1976.
[160] V. Hernandez-Gea, S.L. Friedman, Pathogenesis of liver ﬁbrosis, Annu. Rev.
Pathol. 6 (2011) 425–456.
[161] D.R. Triger, T.D. Boyer, J. Levin, Portal and systemic bacteraemia and
endotoxaemia in liver disease, Gut 19 (1978) 935–939.
[162] J.P. Nolan, The role of intestinal endotoxin in liver injury: a long and evolving
history, Hepatology 52 (2010) 1829–1835.
[163] R. Wiest, G. Garcia-Tsao, Bacterial translocation (Bt) in cirrhosis, Hepatology 41
(2005) 422–433.
[164] R.S. Lin, F.Y. Lee, S.D. Lee, Y.T. Tsai, H.C. Lin, R.H. Lu, W.C. Hsu, C.C. Huang, S.S.
Wang, K.J. Lo, Endotoxemia in patients with chronic liver diseases: relationship
to severity of liver diseases, presence of esophageal varices, and hyperdynamic
circulation, J. Hepatol. 22 (1995) 165–172.
[165] D.E. Fouts, M. Torralba, K.E. Nelson, D.A. Brenner, B. Schnabl, Bacterial transloca-
tion and changes in the intestinal microbiome in mouse models of liver disease,
J. Hepatol. 56 (2012) 1283–1292.
[166] E. Seki, B. Schnabl, Role of innate immunity and the microbiota in liver ﬁbrosis:
crosstalk between the liver and gut, J. Physiol. 590 (2012) 447–458.
[167] A.M. Rutenburg, E. Sonnenblick, I. Koven, H.A. Aprahamian, L. Reiner, J. Fine, The
role of intestinal bacteria in the development of dietary cirrhosis in rats, J. Exp.
Med. 106 (1957) 1–14.
[168] S.A. Broitman, L.S. Gottlieb, N. Zamcheck, Inﬂuence of neomycin and ingested
endotoxin in the pathogenesis of choline deﬁciency cirrhosis in the adult rat,
J. Exp. Med. 119 (1964) 633–642.
[169] Q. Zhu, L. Zou, K. Jagavelu, D.A. Simonetto, R.C. Huebert, Z.D. Jiang, H.L. DuPont, V.H.
Shah, Intestinal decontamination inhibits TLR4 dependent ﬁbronectin-mediated
cross-talk between stellate cells and endothelial cells in liver ﬁbrosis in mice,
J. Hepatol. 56 (2012) 893–899.
[170] K. Poelstra, Y. Popov, D.Y. Sverdlov, A. Sharma, D. Schuppan, Gut-derived
bacterial products drive progression of liver ﬁbrosis in Mdr2−/− mice: involve-
ment of Lps and TLR4, Hepatology 50 (2009) 819A.
[171] E. Gabele, K. Dostert, C. Hofmann, R. Wiest, J. Scholmerich, C. Hellerbrand, F.
Obermeier, DSS induced colitis increases portal LPS levels and enhances hepatic
inﬂammation and ﬁbrogenesis in experimental NASH, J. Hepatol. 55 (2011)
1391–1399.
[172] M. Yoneda, K. Izawa, A. Hirooka, K. Hayashida, S. Wakitani, Indicators of superior
glenoid labral detachment on magnetic resonance imaging and computed
tomography arthrography, J. Shoulder Elbow Surg. 7 (1998) 2–12.
1016 P. Huebener, R.F. Schwabe / Biochimica et Biophysica Acta 1832 (2013) 1005–1017[173] H. Ni, M. Nitta, H. Komatsu, S. Kojima, S. Suzuki, S. Harada, K. Tsuboi, S. Banno, A.
Wakita, M. Yazaki, L. Ren, T. Kato, R. Ueda, Detection of bcr/abl fusion transcripts
by semiquantitative multiplex RT-PCR combined with a colormetric assay in Ph
positive leukemia, Cancer Lett. 124 (1998) 173–180.
[174] F. Isayama, I.N. Hines, M. Kremer, R.J. Milton, C.L. Byrd, A.W. Perry, S.E.
McKim, C. Parsons, R.A. Rippe, M.D. Wheeler, Lps signaling enhances hepatic
ﬁbrogenesis caused by experimental cholestasis in mice, Am. J. Physiol.
Gastrointest. Liver Physiol. 290 (2006) G1318–G1328.
[175] H. Wakita, K. Matsushita, K. Nishimura, Y. Tokura, F. Furukawa, M. Takigawa,
Sphingosylphosphorylcholine stimulates proliferation and upregulates cell
surface-associatedplasminogen activator activity in culturedhuman keratinocytes,
J. Invest. Dermatol. 110 (1998) 253–258.
[176] Y.H. Paik, R.F. Schwabe, R. Bataller, M.P. Russo, C. Jobin, D.A. Brenner, Toll-like
receptor 4 mediates inﬂammatory signaling by bacterial lipopolysaccharide in
human hepatic stellate cells, Hepatology 37 (2003) 1043–1055.
[177] H. Huang, M.L. Shiffman, S. Friedman, R. Venkatesh, N. Bzowej, O.T. Abar,
C.M. Rowland, J.J. Catanese, D.U. Leong, J.J. Sninsky, T.J. Layden, T.L.
Wright, T. White, R.C. Cheung, A 7 gene signature identiﬁes the risk of de-
veloping cirrhosis in patients with chronic hepatitis C, Hepatology 46
(2007) 297–306.
[178] Y. Li, M. Chang, O. Abar, V. Garcia, C. Rowland, J. Catanese, D. Ross, S. Broder, M.
Shiffman, R. Cheung, T. Wright, S.L. Friedman, J. Sninsky, Multiple variants in
Toll-like receptor 4 gene modulate risk of liver ﬁbrosis in Caucasians with
chronic hepatitis C infection, J. Hepatol. 51 (2009) 750–757.
[179] B.V. Martin-Murphy, M.P. Holt, C. Ju, The role of damage associated molecular
pattern molecules in acetaminophen-induced liver injury in mice, Toxicol.
Lett. 192 (2010) 387–394.
[180] A. Tsung, R. Sahai, H. Tanaka, A. Nakao, M.P. Fink, M.T. Lotze, H. Yang, J. Li, K.J. Tracey,
D.A. Geller, T.R. Billiar, The nuclear factor Hmgb1 mediates hepatic injury after mu-
rine liver ischemia–reperfusion, J. Exp. Med. 201 (2005) 1135–1143.
[181] T.A. Wynn, Integrating mechanisms of pulmonary ﬁbrosis, J. Exp. Med. 208
(2011) 1339–1350.
[182] A.B. Imaeda, A. Watanabe, M.A. Sohail, S. Mahmood, M. Mohamadnejad, F.S.
Sutterwala, R.A. Flavell, W.Z. Mehal, Acetaminophen-induced hepatotoxicity in
mice is dependent on TLR9 and the Nalp3 inﬂammasome, J. Clin. Invest. 119
(2009) 305–314.
[183] A. Asea, M. Rehli, E. Kabingu, J.A. Boch, O. Bare, P.E. Auron, M.A. Stevenson, S.K.
Calderwood, Novel signal transduction pathway utilized by extracellular
Hsp70: role of Toll-like receptor (TLR) 2 and TLR4, J. Biol. Chem. 277 (2002)
15028–15034.
[184] J.Y. Song, L. Li, J.B. Ahn, J.G. Park, J.S. Jo, D.H. Park, H.K. Jang, J.J. Jang, M.J. Lee,
Acute liver toxicity by carbon tetrachloride in Hsp70 knockout mice, Exp.
Toxicol. Pathol. 59 (2007) 29–34.
[185] Z.M. Bamboat, V.P. Balachandran, L.M. Ocuin, H. Obaid, G. Plitas, R.P. DeMatteo,
Toll-like receptor 9 inhibition confers protection from liver ischemia–reperfusion
injury, Hepatology 51 (2010) 621–632.
[186] J. Xu, X. Zhang, M. Monestier, N.L. Esmon, C.T. Esmon, Extracellular histones are
mediators of death through TLR2 and TLR4 in mouse fatal liver injury,
J. Immunol. 187 (2011) 2626–2631.
[187] G. Szabo, A. Velayudham, L. Romics Jr., P. Mandrekar, Modulation of non-alcoholic
steatohepatitis by pattern recognition receptors inmice: the role of Toll-like recep-
tors 2 and 4, Alcohol. Clin. Exp. Res. 29 (2005) 140S–145S.
[188] C.A. Rivera, L. Gaskin, M. Allman, J. Pang, K. Brady, P. Adegboyega, K. Pruitt,
Toll-like receptor-2 deﬁciency enhances non-alcoholic steatohepatitis, BMC
Gastroenterol. 10 (2010) 52.
[189] P. Hartmann, M. Haimerl, M. Mazagova, D.A. Brenner, B. Schnabl, Toll-like recep-
tor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I
contribute to liver ﬁbrosis in mice, Gastroenterology 143 (5) (2012)
1330–1340, e1.
[190] M.T. Bility, L. Zhang, M.L. Washburn, T.A. Curtis, G.I. Kovalev, L. Su, Generation of
a humanized mouse model with both human immune system and liver cells to
model hepatitis C virus infection and liver immunopathogenesis, Nat. Protoc. 7
(2012) 1608–1617.
[191] H. Azuma, N. Paulk, A. Ranade, C. Dorrell, M. Al-Dhalimy, E. Ellis, S. Strom, M.A.
Kay, M. Finegold, M. Grompe, Robust expansion of human hepatocytes in
Fah−/−/Rag2−/−/Il2rg−/− mice, Nat. Biotechnol. 25 (2007) 903–910.
[192] J.P. Pradere, J.S. Troeger, D.H. Dapito, A.A. Mencin, R.F. Schwabe, Toll-like recep-
tor 4 and hepatic ﬁbrogenesis, Semin. Liver Dis. 30 (2010) 232–244.
[193] G.N. Kalambokis, E.V. Tsianos, Rifaximin reduces endotoxemia and improves
liver function and disease severity in patients with decompensated cirrhosis,
Hepatology 55 (2012) 655–656.
[194] G.N. Kalambokis, A. Mouzaki, M. Rodi, E.V. Tsianos, Rifaximin for the prevention of
spontaneous bacterial peritonitis, World J. Gastroenterol. 18 (2012) 1700–1702.
[195] A. Velayudham, A. Dolganiuc, M. Ellis, J. Petrasek, K. Kodys, P. Mandrekar, G.
Szabo, Vsl#3 probiotic treatment attenuates ﬁbrosis without changes in
steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice,
Hepatology 49 (2009) 989–997.
[196] J.M. Beck, V.B. Young, G.B. Huffnagle, The microbiome of the lung, Transl. Res.
160 (4) (2012) 258–266.
[197] H. Zhao, S.W. Leu, L. Shi, R. Dedaj, G. Zhao, H.G. Garg, L. Shen, E. Lien, K.A.
Fitzgerald, A. Shiedlin, H. Shen, D.A. Quinn, C.A. Hales, TLR4 is a negative regulator
in noninfectious lung inﬂammation, J. Immunol. 184 (2010) 5308–5314.
[198] H.Z. Yang, J.P. Wang, S. Mi, H.Z. Liu, B. Cui, H.M. Yan, J. Yan, Z. Li, H. Liu, F. Hua, W.
Lu, Z.W. Hu, TLR4 activity is required in the resolution of pulmonary inﬂamma-
tion and ﬁbrosis after acute and chronic lung injury, Am. J. Pathol. 180 (2012)
275–292.[199] A. Paun, J. Fox, V. Balloy, M. Chignard, S.T. Qureshi, C.K. Haston, Combined TLR2
and TLR4 deﬁciency increases radiation-induced pulmonary ﬁbrosis in mice, Int.
J. Radiat. Oncol. Biol. Phys. 77 (2010) 1198–1205.
[200] W.J. Brickey, I.P. Neuringer, W. Walton, X. Hua, E.Y. Wang, S. Jha, G.D.
Sempowski, X. Yang, S.L. Kirby, S.L. Tilley, J.P. Ting, Myd88 provides a protective
role in long-term radiation-induced lung injury, Int. J. Radiat. Biol. 88 (2012)
335–347.
[201] P. Gasse, N. Riteau, S. Charron, S. Girre, L. Fick, V. Petrilli, J. Tschopp, V. Lagente,
V.F. Quesniaux, B. Ryffel, I. Couillin, Uric acid is a danger signal activating NALP3
inﬂammasome in lung injury inﬂammation and ﬁbrosis, Am. J. Respir. Crit. Care
Med. 179 (2009) 903–913.
[202] E. Doz, N. Noulin, E. Boichot, I. Guenon, L. Fick, M. Le Bert, V. Lagente, B. Ryffel, B.
Schnyder, V.F. Quesniaux, I. Couillin, Cigarette smoke-induced pulmonary
inﬂammation is TLR4/Myd88 and Il-1r1/Myd88 signaling dependent, J.
Immunol. 180 (2008) 1169–1178.
[203] H. Wu, J. Ma, P. Wang, T.M. Corpuz, U. Panchapakesan, K.R. Wyburn, S.J.
Chadban, HMGB1 contributes to kidney ischemia reperfusion injury, J. Am.
Soc. Nephrol. 21 (2010) 1878–1890.
[204] H. Wu, G. Chen, K.R. Wyburn, J. Yin, P. Bertolino, J.M. Eris, S.I. Alexander, A.F.
Sharland, S.J. Chadban, TLR4 activation mediates kidney ischemia/reperfusion
injury, J. Clin. Invest. 117 (2007) 2847–2859.
[205] Y. Oyama, T. Hashiguchi, N. Taniguchi, S. Tancharoen, T. Uchimura, K.K. Biswas,
K. Kawahara, T. Nitanda, Y. Umekita, M. Lotz, I. Maruyama, High-mobility
group box-1 protein promotes granulomatous nephritis in nephropathy, Lab.
Invest. 90 (2010) 853–866.
[206] F. Sato, S. Maruyama, H. Hayashi, I. Sakamoto, S. Yamada, T. Uchimura, Y. Morita,
Y. Ito, Y. Yuzawa, I. Maruyama, S. Matsuo, High mobility group box chromosomal
protein 1 in patients with renal diseases, Nephron Clin. Pract. 108 (2008)
c194–c201.
[207] D.L. Rosin, M.D. Okusa, Dangers within: damp responses to damage and cell
death in kidney disease, J. Am. Soc. Nephrol. 22 (2011) 416–425.
[208] M.D. Saemann, T. Weichhart, M. Zeyda, G. Stafﬂer, M. Schunn, K.M. Stuhlmeier,
Y. Sobanov, T.M. Stulnig, S. Akira, A. von Gabain, U. von Ahsen, W.H. Horl, G.J.
Zlabinger, Tamm–Horsfall glycoprotein links innate immune cell activation
with adaptive immunity via a Toll-like receptor-4-dependent mechanism, J.
Clin. Invest. 115 (2005) 468–475.
[209] J.C. Leemans, G. Stokman, N. Claessen, K.M. Rouschop, G.J. Teske, C.J.
Kirschning, S. Akira, T. van der Poll, J.J. Weening, S. Florquin, Renal-associated
TLR2 mediates ischemia/reperfusion injury in the kidney, J. Clin. Invest. 115
(2005) 2894–2903.
[210] A.A. Shigeoka, T.D. Holscher, A.J. King, F.W. Hall, W.B. Kiosses, P.S. Tobias, N.
Mackman, D.B. McKay, TLR2 is constitutively expressed within the kidney and
participates in ischemic renal injury through both Myd88-dependent and
-independent pathways, J. Immunol. 178 (2007) 6252–6258.
[211] P.N. Cunningham, Y. Wang, R. Guo, G. He, R.J. Quigg, Role of Toll-like receptor 4
in endotoxin-induced acute renal failure, J. Immunol. 172 (2004) 2629–2635.
[212] B. Zhang, G. Ramesh, S. Uematsu, S. Akira, W.B. Reeves, TLR4 signaling mediates
inﬂammation and tissue injury in nephrotoxicity, J. Am. Soc. Nephrol. 19 (2008)
923–932.
[213] W.P. Pulskens, E. Rampanelli, G.J. Teske, L.M. Butter, N. Claessen, I.K. Luirink, T.
van der Poll, S. Florquin, J.C. Leemans, TLR4 promotes ﬁbrosis but attenuates tu-
bular damage in progressive renal injury, J. Am. Soc. Nephrol. 21 (2010)
1299–1308.
[214] M.T. Campbell, K.L. Hile, H. Zhang, H. Asanuma, B.A. Vanderbrink, R.R. Rink, K.K.
Meldrum, Toll-like receptor 4: a novel signaling pathway during renal
ﬁbrogenesis, J. Surg. Res. 168 (2011) e61–e69.
[215] P. Chowdhury, S.H. Sacks, N.S. Sheerin, Endogenous ligands for TLR2 and TLR4
are not involved in renal injury following ureteric obstruction, Nephron Exp.
Nephrol. 115 (2010) e122–e130.
[216] J.C. Leemans, L.M. Butter, W.P. Pulskens, G.J. Teske, N. Claessen, T. van der Poll, S.
Florquin, The role of Toll-like receptor 2 in inﬂammation and ﬁbrosis during
progressive renal injury, PLoS One 4 (2009) e5704.
[217] T.T. Braga, M. Correa-Costa, Y.F. Guise, A. Castoldi, C.D. De Oliveira, M.I. Hyane,
M.A. Cenedeze, S.A. Teixeira, M.N. Muscara, K.R. Perez, I.M. Cuccovia, A.
Pacheco-Silva, G.M. Goncalves, N.O. Camara, Myd88 signaling pathway is
involved in renal ﬁbrosis by favoring a Th2 immune response and activating
alternative M2 macrophages, Mol. Med. 18 (1) (2012) 1231–1239.
[218] V. Skuginna, M. Lech, R. Allam, M. Ryu, S. Clauss, H.E. Susanti, C. Rommele,
C. Garlanda, A. Mantovani, H.J. Anders, Toll-like receptor signaling and
SIGIRR in renal ﬁbrosis upon unilateral ureteral obstruction, PLoS One 6
(2011) e19204.
[219] Q. Lin, L. Wang, Y. Lin, X. Liu, X. Ren, S. Wen, X. Du, T. Lu, S.Y. Su, X. Yang,
W. Huang, S. Zhou, F. Wen, S.B. Su, Toll-like receptor 3 ligand polyinosinic:
polycytidylic acid promotes wound healing in human and murine skin, J.
Invest. Dermatol. 132 (2012) 2085–2092.
[220] T. Sato, M. Yamamoto, T. Shimosato, D.M. Klinman, Accelerated wound healing
mediated by activation of Toll-like receptor 9, Wound Repair Regen. 18 (2010)
586–593.
[221] M. Yamamoto, T. Sato, J. Beren, D. Verthelyi, D.M. Klinman, The acceleration of
wound healing in primates by the local administration of immunostimulatory
Cpg oligonucleotides, Biomaterials 32 (2011) 4238–4242.
[222] J. Wang, K. Hori, J. Ding, Y. Huang, P. Kwan, A. Ladak, E.E. Tredget, Toll-like recep-
tors expressed by dermal ﬁbroblasts contribute to hypertrophic scarring, J. Cell.
Physiol. 226 (2011) 1265–1273.
[223] G.A. Farina, M.R. York, M. Di Marzio, C.A. Collins, S. Meller, B. Homey, I.R. Rifkin,
A. Marshak-Rothstein, T.R. Radstake, R. Lafyatis, Poly(I:C) drives type I Ifn- and
1017P. Huebener, R.F. Schwabe / Biochimica et Biophysica Acta 1832 (2013) 1005–1017Tgfbeta-mediated inﬂammation and dermal ﬁbrosis simulating altered gene
expression in systemic sclerosis, J. Invest. Dermatol. 130 (2010) 2583–2593.
[224] T. Shishido, N. Nozaki, S. Yamaguchi, Y. Shibata, J. Nitobe, T. Miyamoto, H. Takahashi,
T. Arimoto, K. Maeda, M. Yamakawa, O. Takeuchi, S. Akira, Y. Takeishi, I. Kubota,
Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction,
Circulation 108 (2003) 2905–2910.
[225] J. Mersmann, K. Habeck, K. Latsch, R. Zimmermann, C. Jacoby, J.W. Fischer, C.
Hartmann, J. Schrader, C.J. Kirschning, K. Zacharowski, Left ventricular dilation
in Toll-like receptor 2 deﬁcient mice after myocardial ischemia/reperfusion
through defective scar formation, Basic Res. Cardiol. 106 (2011) 89–98.
[226] A. Riad, S. Jager, M. Sobirey, F. Escher, A. Yaulema-Riss, D. Westermann, A.
Karatas, M.M. Heimesaat, S. Bereswill, D. Dragun, M. Pauschinger, H.P.
Schultheiss, C. Tschope, Toll-like receptor-4 modulates survival by induction of
left ventricular remodeling after myocardial infarction in mice, J. Immunol. 180
(2008) 6954–6961.[227] L. Timmers, J.P. Sluijter, J.K. van Keulen, I.E. Hoefer, M.G. Nederhoff, M.J.
Goumans, P.A. Doevendans, C.J. van Echteld, J.A. Joles, P.H. Quax, J.J. Piek, G.
Pasterkamp, D.P. de Kleijn, Toll-like receptor 4 mediates maladaptive left
ventricular remodeling and impairs cardiac function after myocardial infarction,
Circ. Res. 102 (2008) 257–264.
[228] P. Blyszczuk, G. Kania, T. Dieterle, R.R. Marty, A. Valaperti, C. Berthonneche, T.
Pedrazzini, C.T. Berger, S. Dirnhofer, C.M. Matter, J.M. Penninger, T.F. Luscher, U.
Eriksson, Myeloid differentiation factor-88/interleukin-1 signaling controls cardiac
ﬁbrosis and heart failure progression in inﬂammatory dilated cardiomyopathy,
Circ. Res. 105 (2009) 912–920.
[229] T. Ha, F. Hua, Y. Li, J. Ma, X. Gao, J. Kelley, A. Zhao, G.E. Haddad, D.L. Williams,
I.W. Browder, R.L. Kao, C. Li, Blockade of Myd88 attenuates cardiac hypertro-
phy and decreases cardiac myocyte apoptosis in pressure overload-induced
cardiac hypertrophy in vivo, Am. J. Physiol. Heart Circ. Physiol. 290 (2006)
H985–H994.
